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ABSTRACT: Influence of anti-CD44 on B cell activation
Tiana Lynn Wyant
Lymphocyte activation and trafficking are indispensable to the immune system.
CD44, an adhesion molecule, plays important roles in T cell activation, lymphocyte
homing/trafficking, and tumor metastasis. Although the functions of CD44 have been
shown in T cells and other leukocytes, little is known about its role in B cells. The effects
of CD44 cross-linking on murine B cell activation via CD40L/IL-4 was explored using
the anti-CD44 mAbs RK3G9 and IM7. Immobilized RK3G9 and IM7 could strongly
inhibit B cell proliferation and Ig production, with IgE inhibition being prominent.
Soluble anti-CD44 had no effect. The inhibitory effect of RK3G9 was not influenced by
addition of anti-FcγRII, indicating no role for the inhibitory receptor. The effects of
delayed addition of immobilized anti-CD44 mAbs were studied, and the results indicated
no inhibition after 96 hrs of culture. B cells were also activated by either LPS or anti-IgM
F(ab’)2. While LPS-induced B cell activation was inhibited by immobilized anti-CD44
mAbs, anti-IgM activation was refractory. Interestingly, addition of both anti-IgM and
CD40L or LPS resulted in some modulation of the inhibitory activity. Additionally,
FACS and Elispot revealed that RK3G9-treated cells had reduced numbers of plasma
cells. Taken together, these results suggest that CD44 cross-linking could control
polyclonal B cell activation by CD40L, but allow sIgM/CD40L activation to continue.

INTRODUCTION
I. CD44: Adhesion Receptor.
A. Structure. CD44 is a single pass, highly polymorphic type II cell surface glycoprotein
ranging in size from 80 to 250 kDa and is a member of the hyaldherin or link protein
superfamily.1,2 This adhesion receptor has four major domains: the distal extracellular,
membrane-proximal extracellular, transmembrane, and cytoplasmic domain (Fig. 1). The
distal extracellular domain is responsible for the binding of ligand. The membrane
proximal extracellular domain contains the site where additional “variant” exons – which
encode additions to the CD44 protein – may be spliced into the CD44 mRNA transcript
to generate multiple variant isoforms of the CD44 molecule. The transmembrane domain
is typical of single-pass proteins, but studies using site-directed mutagenesis have
generated data which suggests that lipids or accessory membrane proteins may interact
with the transmembrane domain of CD44 to modulate ligand binding. The 70-amino-acid
(a.a.) cytoplasmic tail is present in most isoforms of CD44 and data indicates that it
functions to interact with cytoskeletal components and also is involved in intracellular
signaling. It can also influence the binding of ligand to CD44.3-5
CD44 is a single gene with a total of 20 exons and is located on the short arm of
chromosome 11 in the human. Exons 1-5, 16-18, and 20 comprise the most often
expressed form of CD44, called CD44s (CD44 standard) or CD44H (because this is the
predominant form expressed on hematopoietic cells). CD44s, then, is expressed when
direct splicing of exon 5 to exon 16 occurs (see Fig. 2), skipping the variant exons (exons
6-15 = v1-v10). CD44s is 363 amino acids long. Exon 19 encodes the short tail (three
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Figure 1. Structure of the CD44 glycoprotein. CD44 has four domains – the
membrane-distal extracellular domain (ligand-binding domain), the membrane-proximal
extracellular domain (where variant exons may be inserted), transmembrane region, and
cytoplasmic tail. When the CD44 tail is phosphorylated due to ligand binding, contact
with actin and other cytoskeletal components occurs, leading to cytoskeletal
rearrangement and a change in the phenotype of the cell. (Schematic is from “The
Hyaluronan

Receptor,

CD44”

by

Warren

Knudson

and

http://www.glycoforum.gr.jp/science/hyaluronan/HA10/HA10E.html.

Cheryl

Knudson,

Reprinted

permission from Editors at Glycoforum.com and Warren Knudson, author)

with

3

4

Figure 2. Gene Structure of CD44. CD44 has 20 exons total, but only nine (1-5, 16-18,
20) are expressed in the standard isoform (CD44s). The variant exons (6-15, also called
v1-v10) are alternatively spliced into the mRNA to create, theoretically, hundreds of
different isoforms. Note that exon 19 is the short tailed version of CD44 and is rarely
employed in any isoform. (Schematic is drawn with inspiration from “The Hyaluronan
Receptor, CD44” by Warren Knudson and Cheryl Knudson, on the web site
www.glycoforum.gr.jp
[http://www.glycoforum.gr.jp/science/hyaluronan/HA10/HA10E.html]
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6
amino acids) of CD44 and is rarely used. Studies have suggested that this nearly
“tailless” CD44 isoform negatively regulates CD44-mediated uptake of hyaluronic acid
(ligand). When transfected into a chondrocyte, this truncated tail isoform acts as a
dominant negative receptor, causing a loss of the capacity to either bind or internalize
hyaluronan6,7 and a loss of Smad signaling.8 The 10 variant exons are numbered 6
through 15 and are utilized by alternative mRNA splicing. The isoform nomenclature,
when a variant exon is added to the standard CD44 protein, is “CD44v1” to refer to
“CD44s plus exon 6” (the first variant exon, v1), and so on, up to v10. A CD44 molecule
containing variant exons 2 and 5-7 is named CD44v2,v5-7. Theoretically, any number
and combination of variant exons may be added to the CD44 protein to generate hundreds
of different isoforms; thus far, about 30 have been identified. Recently, it has been found
that certain cell types can use intronic sequence as part of the coding sequence. For
example, synovial cells isolated from the joints of individuals suffering from rhuematoid
arthritis (RA) express a CD44v3-10 mRNA transcript that includes an extra trinucleotide
between variant exons 4 and 5. This merely adds an alanine and does not interfere with
the reading frame. Investigators found that cells transfected with this variant isoform of
CD44v3-10 (named CD44vRA) can bind more soluble Fibroblast Growth Factor
Receptor-1 (FGFR1) than could CD44v3-10-expressing cells, suggesting that these
CD44vRA-expressing cells in RA patients have enhanced FGF-R1 activation,9 which
indicates increased disease susceptibility. Another example of intronic sequence use is
with a group of alternatively spliced CD44 isoforms termed “soluble CD44”. In mouse
embryonic muscle and cartilage tissues, CD44v8-10 was found to have additional coding
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sequence derived from intronic sequence between v9 and v10. Of the four transcripts
found, two contained extensions of v9 and two had a “new exon”; the common feature
these four transcripts share is a stop codon, which results in a protein truncated within the
membrane-proximal extracellular domain.10
Individual cells can repeatedly change the splicing of their CD44 pre-mRNA,
consistent with the responses that need to be made in reference to the extracellular and
intracellular microenvironment. The CD44s protein is approximately 37 kDa prior to
glycosylation; after addition of the appropriate N-linked and O-linked oligosaccharides,
the final molecular mass is 80-100 kDa. There are at least five conserved N-glycosylation
sites in the N-terminal domain and two chondroitin sulphate attachment sites on the exon
5 product.11 There are also several possible O-linked glycosylation sites in the membrane
proximal region and consensus attachment sites for heparin suphate, keratin sulphate, and
sialic acid on the standard extracellular domain. As noted before, hyaluronic acid (HA) is
the major ligand for CD44. The structure of HA, a glycosaminoglycan, is characterized as
a linear polymer. There are three places on the CD44 molecule that contact HA and form
the binding sites; these binding sites are basic amino acid clusters, with specific and
critical arginine residues.11
The addition of variant exons can introduce new glycosylation sites, including
serine/threonine-rich regions for O-glycosylation,12 glycosaminoglycan attachment
consensus SGXG motifs,13 and tyrosine sulfation.14 The molecular mass may reach up to
250 kDa. Different CD44 isoforms can have specific patterns of glycosylation and these
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additions have repercussions on the ability of CD44 to bind ligand.15 Interestingly, the
mouse has 10 variant exons, but the human has nine.3,4,16,17
B. Expression. CD44s is expressed ubiquitously on mesenchymal and hematopoietic cell
types.3

It has been also found on cells of the central nervous system, lung, liver,

pancreas, and epidermis. CD44v has a more restricted expression profile: it is expressed
on activated lymphocytes, macrophages, selected epithelial cells, and keratinocytes;17-19
the level of expression, as well as the particular CD44 isoform, varies according to cell
type and activation state.16,20 The primary ligand for CD44 is hyaluronate,19,21 a major
component of the extracellular matrix, although there are other ligands, including
fibronectin,22 collagen,23 laminin, chondroitin sulfate, L and E selectins, and the MHC
class II invariant chain,24,25 among others. The hyaluronan (hyaluronic acid, HA) binding
domain is highly conserved in all CD44 isoforms and contains two clusters of positively
charged amino acids, and these bind a six-sugar sequence of HA.5,26 The ligand
specificity of CD44 is markedly influenced by post-translational modifications, primarily
glycosylation,27 as well as the extensive alternative mRNA splicing3 that leads to the
generation of variant isoforms. Glycosylation has been shown to have an additive effect
on CD44 ligand binding; glycosaminoglycans (long chains of repeating disaccharides)
such as chondroitin sulfate or heparin sulfate have highly charged sulfate and carboxylate
groups. These contribute to a negatively charged environment, which naturally attracts
positive ions, and so create an osmotic potential. This can then influence CD44 ligand
binding. The data suggests that CD44v isoforms have a reduced ability to bind
hyaluronate and that it is due to the degree of glycosylation.12 Binding studies have found
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that CD44v can bind HA as efficiently as CD44s if the O-linked glycosylation is removed
prior to binding,12 and N-linked glycosylation has been shown to inhibit HA binding as
well.28,29 Phosphorylation of serine in the cytoplasmic portion of CD44 also increases its
capacity to bind HA, as well as increasing the binding of ankyrin to the cytoplasmic tail
of CD44.4,30 This has been implicated in downstream events which lead to cell migration.
Other factors influencing HA binding are the distribution of CD44 on the cell surface (ie,
within a lipid raft or not) and the ability of the CD44 present to cluster once HA is bound
(which promotes tighter binding).31
CD44 is transcriptionally upregulated by proinflammatory cytokines such as
interleukin-1 (IL-1) and growth factors (TGF-β, EGF, BMP-7).17,32-34 These can have an
impact on CD44 splicing.
CD44 can be found in three states of activation on cells: active, inducible, and
inactive. The “state of activation” simply refers to its functional ability to bind
hyaluronan. The “active state” CD44 constitutively binds hyaluronan, whereas the
“inducible state” CD44 binds HA weakly or not at all, unless it is activated by inducing
mAbs, cytokines, or growth factors. The inactive CD44 simply does not bind HA, even in
the presence of inducing agents. It has been suggested that this is a mechanism to prevent
unnecessary engagement of the receptor, as both CD44 and its prinicipal ligand are
ubiquitously expressed.3 These three states of activation can be directly correlated with
the level of glycosylation on individual CD44 proteins; low glycosylation is found on
active state CD44, while intermediate and high glycosylation levels are found on
inducible and inactive state CD44, respectively.19,24,35
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C. Function. There are multiple known functions for CD44. It acts as a co-receptor,
functions in cell-cell aggregation, anchors pericellular matrix, acts as a docking protein
for matrix metalloproteinases (MMPs), functions in cell-matrix and matrix-cell signaling,
mediates

cell

migration,

and

ligation

can

result

in

receptor-mediated

internalization/degradation of hyaluronan.4,59 One example is CD44v3, which bears a
heparin-sulfate proteoglycan chain; it can bind basic growth factors such as fibroblast
growth factors (FGFs), which are essential to proper development of the limb bud.
More specific to the immune system, CD44 is involved with cellular adhesion
(migration and aggregation), lymphocyte activation,36,37 angiogenesis, and release of
cytokines.17 A recent paper by Bradl, et al, reported that CD44 is dispensable for B cell
lymphopoeisis, and that CD44-deficient B cells, activated by stimuli such as IL-4/CD40,
IL-4/anti-IgM HC, and LPS, are normal in their responses.38 Another report on CD44-/mice agrees that the mice develop normally but also shows that lymphocyte homing to
the thymus and lymph nodes is impaired.39

A separate report by Stoop, et al,

investigating the responses of CD44-/- leukocytes to acute or chronic inflammation,
suggests that CD44 can actually interfere with homing to lymphoid tissues under
inflammatory conditions.40 That is, there is increased homing to inflamed tissues in the
presence of CD44. This is based on work done in mice with induced acute or chronic
inflammatory conditions and showed that CD44-/- lymphocytes transferred from mice
with collagen-induced arthritis into wild-type mice with arthritis preferentially homed to
lymph nodes and were slower to enter inflamed synovial joints than the wild type
lymphocytes.
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CD44 has no inherent receptor kinase or phosphatase activity; however, it is
coupled to classical signaling molecules such as c-Met, members of the ErbB family
receptor tyrosine kinases, and TGF-βRI.41-46 In T cells, CD44 has been shown to be
physically and functionally associated with p56lck47 as well as with Fyn.48 The
cytoplasmic domain of CD44 does not seem to contain any Src family sequence motif,
but CD44 signaling may be thought of as being similar to that of integrins: an indirect
transfer of information about the state of the extracellular matrix via “linker” proteins that
become associated with the CD44 cytoplasmic domain after the “activation event” has
occurred. A precise definition of the “CD44 signaling complex activation event” has not
yet been defined. However, what is known is that there are two ways to “activate” CD44,
depending on the context in which the CD44-bearing cell lives: in blood-borne cells, as
well as migrating embryonic, endothelial, or malignant cells, unoccupied CD44 receptors
undergo “activation” when they are bound by hyaluronan. The other scenario is tissues
where hyaluronan is ubiquitous: here, multivalent hyaluronan bound by clustered CD44
is the normal resting state of the cells, and the “activation event” is begun when there is
disruption of the CD44-hyaluronan interactions (by a variety of events detailed below).
When CD44 on blood-borne or migrating cells binds high molecular weight
hyaluronan, CD44 clusters and this results in multiple intracellular events. The kinases cSrc, FAK, Rho, and Rac are activated,6,8,49 leading to closer CD44-actin cytoskeleton
associations and the recruitment and activation of other signaling molecules which are
involved in cell migration. CD44 also co-immunoprepitates with Lyn, Fyn, Lck, and Hck,
and in v-Src-transformed cells, CD44-HA intereactions increase the phosphorylation of
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Akt and MAP kinase.50 RANTES typically signals via a G-protein coupled chemokine
receptor, but can also signal via CD44 by binding to the glycosaminoglycan chains of
certain CD44 variants which bear these chains and activate p44/p42 MAP kinase.
Additionally, when CD44 is cross-linked by monoclonal antibodies, Lck is activated,
ZAP-70 is tyrosine phosphorylated, and Pyk2 is phosphorylated in T lymphocytes.51.
In tissues such as cartilage, where the quiescent state of CD44-HA interaction is
multivalent binding (stable cell-matrix interactions), disruption of this binding by
degradation of hyaluronan,52,53 cleavage of the extracellular domain of CD44,54,55 soluble
CD44 competing for HA,56 or the presence (and thus competition) of small molecular
weight hyaluronan oligosaccharides,57-59 can cause CD44 signaling events. The major
effect of this release of extracellular restraints imposed by CD44-multivalent HA binding
is that the cell’s sensitivity to apoptosis may increase substantially. Nitric oxide (NO) is
released when HA oligosaccharides are added to many cells, including chondrocytes, and
NO can downregulate PI-3 kinase and induce apoptosis in chondrocytes.60,61 In addition,
hyaluronan can reduce anti-Fas-mediated apoptosis in chondrocytes. The pervading
hypothesis, then, is that disruption of stable HA-CD44 interactions results in release of
both CD44 and CD95 clustering, causing the cell surface to be more susceptible to Fas
ligand and its consequent activation of apoptosis.
Apoptosis due to oligosaccharides was also observed in mammary and lung
carcinoma cell lines and in glioma cells.57,62 Initiation of apoptosis was found to be due to
inhibition of PI-3 kinase leading to an inhibition of Akt, BAD, and FKHR
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phosphorylation. The sum effect was that Bcl-2 and caspase-3 activation was inhibited.57
A similar inhibition of PI-3 kinase was observed with the use of anti-CD44 antibodies.63
Other work done on signaling via CD44 has been researched in the context of
tumor progression and dissemination. CD44 is coupled to the tyrosine kinases p185HER2
and c-Src kinase; it is actually linked via disulphide bonds to the former and has a high
affinity binding site to the other. HA binding results in activation of CD44-associated
p185HER2 and increased tumor growth. The CD44-HA interaction also leads to c-Src
stimulation, and this induces increased phosphorylation of the cytoskeletal protein
cortactin, which in turn attentuates its interaction with filamentous actin. This may lead to
cytoskeleton-regulated tumor cell migration.64 Additionally, CD44 can interact with Rho
GTPases (such as RhoA and Rac1, which have roles in cytoskeletal movement and
migration of the cell) and in breast tumor cells, CD44v3,v8-10 is noncovalently linked to
RhoA.65 Rac1 signaling regulates a pathway known to be involved in membrane ruffling,
cellular projections, cell motility, and cell transformation.66,67 The first nineteen residues
of the cytoplasmic domain of CD44 interact with the cytoskeleton via the
ezrin/radixin/moiesin

(ERM)

membrane

linker

proteins,

which

contain

the

phosphatidylinositol 4,5-biphosphate (PIP2) binding motif.66,68 The CD44 cytoplasmic
domain has a 15-amino acid ankyrin binding domain; biochemical analysis (competition
studies) and in vitro mutagenesis, as well as deletion analysis, indicate that the ankyrinbinding domain is required for CD44-mediated "outside-in" and "inside-out" cell
activation events. In addition, CD44-cytoskeleton interaction is known to be coupled with
signal transducing molecules (such as p185HER2 and Src kinases) during tumor cell
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signaling. Overall, the data suggests that this CD44-ankyrin association is pivotal for
promotion of oncogenic signaling and tumor cell transformation.69
Recently, there have been several reports which support a new mechanism for
direct signaling by CD44: it is a 2-step process whereby the CD44 ectodomain is
cleaved, followed by cleavage of the transmembrane (TM) domain; this releases a CD44
intracellular domain (ICD) which can translocate to the nucleus and act as a transcription
factor.54,70,71 It should be noted that this mirrors the mechanism for the Notch receptor.72
Cleavage

of

the

extracellular

domain

can

occur

by

membrane-associated

metallopreteinases (MMPs)73 (specifically MT1-MMP74) or ADAM10.75 Release of the
CD44 ICD is accomplished by γ-secretase cleavage of the TM domain and the CD44 ICD
potentiates activation with the p300/CREB-binding protein (CBP) to activate
transcription of target genes, including the CD44 gene.54 This dual cleavage pathway is
thought to modulate the role of CD44 as a docking protein and co-receptor, and may
regulate cell detachment from hyaluronan during tumor cell migration/invasion.63
Two of the major functions of CD44 within the context of the immune system are
organ-specific homing (particularly lymph node19,21,76,77), and lymphocyte activation.
Lymph node (and Peyer’s Patch) homing occurs via cell-surface CD44 binding to a
protein called mucosal addressin, which is present on the high endothelial venules
(HEV). This binding occurs via the membrane proximal domain of CD44. The variant
CD44v6, which has been shown to be required for activation of T and B lymphocytes,
has a crucial role in the movement and homing of antigen-activated lymphocytes in
lymph nodes.17,78 CD44 and membrane HA is a fairly weak interaction (in comparison to
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integrins and cadherins), and can indeed be an advantage in certain situations involving
lymphocyte-to-lymphocyte exchange of chemical signals. This could account for the
ability of CD44 to mediate T lymphocyte activation and B lymphocyte maturation.79,80
CD44v isoforms have been implicated in conferring both increased growth and metastatic
properties on tumor cells, particularly CD44v6/7.81,82
It has been reported that rolling lymphocytes may sometimes exploit epithelial
cell-surface CD44 glycoprotein instead of selectin for the tethering and rolling process
(the

first

step

in

extravasation),

using

their

own

cell-surface

HA

as

a

countermolecule.3,83,84 This data was shown in experiments tracking leukocyte entry into
infected tissues through inflamed capillaries, as well as in lymphoma migration into
lymph nodes. Other investigators have shown that cell-surface CD44v4-10 (not CD44s)
mediates the rolling of mouse (tumor) cells on HA substrate.84 In addition, studies have
shown that CD44 can mediate leukocyte rolling under physiological flow conditions;85
and Estess, et al, showed that CD44 on T cells can interact with endothelial HA to
mediate rolling under shear stress, with a secondary firm adhesion occurring via VLA4.86 Clark, et al, demonstrated that the rolling of tonsillar lymphocytes on cultured
tonsillar stromal cells was dependent on CD44-HA binding by inhibiting lymphocyte
rolling via addition of anti-CD44 antoantibodies, soluble HA, and hyaluronidase
treatment.21
Lymphocyte CD44-dermal endothelial HA interactions can result in lymphocyte
homing to sites of inflammation.87 Pro-inflammatory cytokines such as TNFα and IL-1
enhance endothelial presentation of HA, thus presenting an immobilized HA surface
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conducive to lymphocyte rolling. This HA is resistant to fluid shear forces as it is
anchored to endothelial CD4488. TNFα also induces TSG-6, another HA-binding protein,
which can present HA to the lymphocytes and facilitates enhanced lymphocyte rolling
and adhesion (over HA without TSG-6).89 It has been shown that CD44-HA interactions
play a key role in mediating lymphocyte rolling to enhance leukocyte adhesion at sites of
inflammation,63 and it has been hypothesized that the inflammatory cascade might also be
affected by the affinity of the appropriate CD44 variant expression on the circulating
lymphocyte, though this has not yet been proven directly.
Ligation of CD44 by anti-CD44 Ab can trigger effector functions in T
lymphocytes,

activate

monocytes,

and

enhance

natural

killer

cell-mediated

cytotoxicity.36,37,90-95 Interaction between hyaluronate and CD44, as well as between antiCD44 mAbs and CD44, results in murine B cell activation and a phenotype closely
resembling a germinal center B cell.96,97
II. B lymphocytes in the Immune System.
A. Introduction. B lymphocytes are members of the adaptive immune system and arise
from lymphoid progenitor stem cells in the bone marrow (see Figure 3 for an overview of
B cell development). They progress through stages – pro-B, pre-B, immature B, and
mature B cell – with the identity of the individual B cell depending on the genes
expressed at each stage and on productive rearrangements of the genes which produce the
B cell receptor Ig (immunoglobulin). As a pro-B cell, there is VDJ rearrangement of the
heavy chain genes; the pre-B cell expresses a “pre-B receptor” (μ chain) combined with a
surrogate light chain; light chain VJ gene rearrangement results in an immature B cell
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Figure 3. This shows a very general overview of B cell development and differention.
(Schematic is drawn with inspiration from Immunology, 4/e, by Roitt, Brostoff, and Male,
1996 Times Mirror International Publishers Unlimited)
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expressing a full-size B cell receptor (membrane IgM); the mature B cell expresses IgD
and IgM. This mature B cell is considered functionally naïve because it has not yet seen
antigen.
B. CD44 and B cells. B cell activation and differentiation are regulated by components in
the surrounding microenvironment.98 During the differentiation of a mature naïve B cell
into an activated B cell, cell-cell interactions, as well as soluble molecules, mediate
phenotypical

changes.

The

involvement

of

cell-matrix

interactions

is

still

uncharacterized, but may represent a novel mechanism for regulation of lymphocyte
activation. It is known that different adhesion molecules and homing receptors, including
selectins, integrins, and members of the Ig superfamily, can influence the cellular
response, and CD44 is a representative adhesion molecule that is capable of affecting B
cell responses.97 The functional role of CD44 on B cells is relatively unknown, although
the protein has been implicated in B cell differentiation and activation in several previous
studies

99-103

. These studies showed that CD44 expression on B cells is rapidly induced

via interaction of CD40-CD40L,104 as well as by IL-5.105 B cells upregulate CD44 upon
activation,20,78,106 and mature mouse B cells can be activated in vivo by interaction of
hyaluronate and CD44.96 During the germinal center reaction, however, CD44 is
downregulated.107-109 CD44 ligation in human B cells also results in upregulation of the
genes for IL-6, IL-1α, and β2-adrenergic receptor (β2-AR) – indicating a role in
immunomodulation and inflammation.110
C. Pathways of B cell Activation.
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C1. CD40 and its ligand CD40L (CD154). CD40, a 45-kD transmembrane
glycoprotein, is a member of the tumor necrosis factor receptor (TNFR) family and is
expressed on B lymphocytes, monocytes, and dendritic cells, as well as endothelial and
epithelial cells. Its ligand, CD40L, is expressed primarily on activated CD4+ T cells.
CD40 signaling (Fig. 4) has important roles in the following functions: 1) promotion of
the activation and differentiation of B cells by T-cell-dependent antigens; 2) germinal
center formation 3) Ig class switching 4) affinity maturation (of Ig on B cells) and 5) the
development of plasma cells and memory B cells.111-113 Binding of CD40L to CD40
causes the CD40 monomer to cluster in lipid rafts in order to propogate the signal; the
cytoplasmic tail of CD40 has binding sites for TRAF (TNF receptor-associated factor)
proteins, which act as adaptor proteins to couple CD40 to the phosphoinositide-3 kinase
(PI3K), phospholipase Cγ (PLC-γ), mitogen-activated protein kinase (MAPK-ERK, p38,
and JNK), and nuclear factor κB (NFκB) signaling pathways. The primary pathway of
interest for this discussion is the NFκB pathway; the others are involved in the inhibition
of genes involved in cell cycle arrest and promotion of genes related to cell cycle
progression. The intracellular domain of CD40 both associates with and signals through
TRAF2, TRAF3, TRAF4, and TRAF6, although recent research has shown that TRAF6
is dispensable; upon oligomerization of CD40, TRAF2, TRAF5, and TRAF6 encourage
the dissociation of NFκB from its inhibitor, IκB. NFκB can then translocate from the
cytoplasm to the nucleus and synergizes with Signal Transducer and Activator of
Transcription-6 (STAT6) to activate the Iε promoter, the first step in class switching by
inducing production of Cε GLTs.111,113,114 Additionally, CD40 can activate signal
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Figure 4. CD40 signaling. The CD40 signaling pathway is shown here. It is a primary B
cell signaling pathway utilized as a costimulatory pathway to induce B cell activation
and, in vivo, germinal center initiation. The IL-4 pathway is also shown. (Schematic is
drawn with inspiration from Geha, et al111)
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transducer and activator of transcription 6 (STAT6) and the Janus kinase 3/STAT3
pathway independently of the TRAFs.
CD40-CD40L ligation also synergizes with IL-4 to induce expression of
activation-induced cytidine deaminase (AID), which is crucial for class switch
recombination (CSR) and also is important for somatic hypermutation. For example,
when B cells switch to IgE, IL-4 signaling leads to STAT6 homodimerization and its
subsequent binding to a response element in the AID gene; CD40 ligation causes a
signaling cascade that leads to NFκB binding to two sites in the AID gene. This synergy
is important - STAT6-deficient mice or NFκB p50-deficient mice have impaired ability
to induce AID expression. This “two signal” requirement – IL-4-induced STAT6 and
CD40-induced NFκB working together to initiate AID expression – seems to be required
to overcome a potential threshold level of AID expression so that CSR to IgE can
occur.111,113,115 Two signals are required for the induction of AID and the eventual
expression of other immunoglobulin isotypes also.
C2. B Cell Receptor (BCR). The B cell antigen receptor (BCR) plays a crucial role in
the development and survival of B lymphocytes as well as the response to antigen. The
BCR is a multiprotein structure composed of membrane Ig (mIg) and Igα (CD79a) plus
Igβ (CD79b) chains, which are noncovalently attached. The mIg is produced from the
rearrangement of VDJ segments for the heavy and light chain genes and functions to bind
antigen, while each Igα and Igβ chain contains a single ITAM (Immunoreceptor
Tyrosine-based Activation Motif). These ITAM motifs contain two tyrosines precisely
spaced, along with a specific amino acid sequence, to provide a binding site for src-
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homology-2(SH2)-domain-containing proteins and thus functions to begin the signal
transduction pathway (Fig 5). CD19 is a B cell coreceptor that lowers the signaling
threshold, thereby augmenting the signals received through the BCR; however, it is not
crucial to B cell development prior to the mature B cell stage. When antigen becomes
bound to mIg and receptor aggregation is induced, the two ITAM sites on Igα/β are
phosphorylated by Src family protein tyrosine kinases (PTK) such as Lyn, Fyn and Blk.
Lyn can have both positive and negative effects on BCR signaling – it is, indeed, vital to
negative regulation of the BCR, as it can phosphorylate ITIMs (Immunoreceptor
Tyrosine-based Inhibition Motif) on FcγRIIb and CD22, both of which play a role in
inhibition of the BCR response. Once src-family PTKs have become active, progressive
amplification of the ITAM phosphorylation occurs and additional effector proteins/lipids
are recruited. Another src-family PTK, Syk, binds to the ITAM with appreciable affinity
via its SH2 domains only once the ITAM is doubly phosphorylated, which facilitates
further Igα/β phosphorylation and subsequent initiation of downstream signaling events.
There is a check and balance system “in the house”. B220 (also known as CD45) is a
transmembrane tyrosine phosphatase that modulates BCR signaling by ensuring that a
small population of the src-family PTKs, such as Lyn, are in a “positive” state of
phosphorylation so that they are in readiness for a response to BCR aggregation. The Cterminal src tyrosine kinase (Csk) counters this by keeping some src PTKs “repressed”
via phosphorylation of their C-terminal inhibitory tyrosine.116-118 BCR ligation leads to
activation

of

phosphatidylinositol-3-kinase

(PI3K),

which

phosphorylates

phosphatidylinositol-4,5-biphosphate, which creates phosphatidylinositol-3,4,5-
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Figure 5. BCR signaling. This diagram shows the relationship of the multiprotein
complex called the BCR and various signaling molecules which mediate and amplify the
signals received; the cascade that is initiated determines the B cell response in
development and survival or to antigen recognition. (Schematic is drawn with inspiration
from Gauld, et al, and Dal Porto, et al116,117)
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triphosphate [PI(3,4,5)P3], also called simply PIP3. This phospholipid then recruits PHdomain containing proteins like the Tec-family kinase Btk or the serine-threonine kinase
Akt, putting them into close proximity to membrane-associated substrates and other
phospholipid-binding pleckstrin homology (PH)-domain containing molecules, and any
or all of these may serve a function in the ongoing signal propogation. CD19, the BCR
co-receptor briefly mentioned earlier, is an integral transmembrane glycoprotein which
associates with CD21 (complement receptor 2, CR2) and CD81 in a tri-molecular
complex; this complex also associates with the BCR via CD21 binding to complement
bound to the antigen. Once BCR ligation has occurred, the tyrosines in the cytoplasmic
tail of CD19 are phosphorylated by Lyn; this creates binding sites for the p85 adaptor
subunit of PI3K, as well as for other SH2-domain containing proteins. The
adaptor/scaffold protein BCAP can also be tyrosine phosphorylated and attract PI3K.
This binding localizes PI3K close to its lipid substrates and increases its catalytic
activity.116-118
Once Lyn, Syk, and Btk have been activated, the adaptor molecule B cell LiNKer
protein (BLNK), which is quickly phosphorylated by Syk following BCR aggregation,
helps to recruit PLCγ2 (via the SH2 domain of PLCγ2), associates with the SH2 domains
of Btk, and functions to couple BCR signaling to [Ca2+]i influx. BLNK acts as a major
platform for the assembly of effector molecules and this is also where the signaling
pathways diverge. PLCγ2 cleaves PI(4,5)P2 into the second messengers inositol 1,4,5trisphosphate (also called IP3) and diacylglycerol (DAG). Creation of IP3 causes
increased [CA2+]i, which is necessary for the activation of numerous transcription factors,
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among them NFκB and N-FAT. DAG activates protein tyrosine kinases (PKCs), and
these regulate the mitogen-activated protein kinase (MAPK) family proteins. Three of the
most important MAPK family proteins, which phosphorylate different sets of
transcription factors, are extracellular signal-regulated kinase (ERK), c-Jun N-terminal
kinase (JNK), and p38 MAPK; ERK activates Elk-1 and c-Myc, JNK activates C-Jun and
ATF-2, and p38 MAPK activates ATF-2 and MAX. Akt and PKC activation both
eventually terminate in NFκB activation and translocation into the nucleus where it
activates the transcription factors Bfl-1 and Oct-2. In summary, these events, illustrated
in Fig. 5 and discussed above, lead to B cell activation and maturation.116,117
C3. LPS – the “innate” activator. Toll-like Receptors (TLR) (Fig. 6) are Type I integral
membrane glycoproteins which act as a “bridge” between the innate and adaptive
systems, since these receptors are found on macrophages, dendritic cells, T cells, and B
cells. Interestingly, they have significant target specificity; TLR proteins recognize a
diverse array of ligands on bacteria, fungi, viruses, and parasites. The ligands are known
as pathogen-associated molecular patterns (PAMPs), and examples are Gram-negative
bacterial lipopolysaccharide (LPS), Gram-positive bacterial peptidoglycan, bacterial
flagellin, DNA, and RNA. The TLR family of proteins has a cytoplasmic tail containing a
toll/IL-1 receptor (TIR) domain, so named because of its similarity to the IL-1 receptor.
This TIR domain is the active motif that initiates signaling when ligand is bound.119-122
Significant expression of TLRs on human B cells is seen only for TLR1 and TLR6-10;
these are upregulated in response to antigen-BCR or CD40 ligation. However, murine B
cells express TLR4 in response to LPS exposure (Fig. 6), and the cells proliferate and
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Figure 6. TLR4 pathway. LPS bound to the TLR4/MD2 proteins initiates a signal
cascade resulting in NFκB activation and the subsequent expression of imfammatory
cytokines and interferons. (Schematic is drawn with inspiration from Fitzgerald, et al119)
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differentiate into plasma cells in vitro. When LPS is present, it will be bound first by
LPS-binding protein (LBP), which is present in serum, and this opsonic activity enhances
the detection of LPS in the blood (by about 300-fold).119 This complex of LBP/LPS will
be bound by CD14, a GPI-linked protein123,124 that has no intrinsic signaling capacity.
LBP is also found as a soluble protein which enhances LPS binding by 1000-fold for
leukocytes that do not express CD14.123,124 TLR4 is expressed on the B cell surface in
complex with MD-2, and this heterodimer participates in recognition of CD14/LPS and
initiates intracellular signaling via two pathways. One is the MyD88-TIRAP (Myeloid
Differentiation factor 88-TIR-domain-containing adaptor protein) pathway, which
regulates the activation of NFκB (which heterodimerizes with AP-1) and related
inflammatory cytokine production; the second is the TRIF-TRAM (TIR domaincontaining adaptor Inducing IFNβ-TRIF-related Adaptor Molecule) pathway (also called
the MyD88-independent pathway), which controls the activation of the transcription
factor interferon regulatory factor-3 (IRF-3) (with STAT1) and the induction of Type I
interferons and costimulatory molecules.119-122
The MyD88-dependent pathway operates as follows: upon stimulation, MyD88 –
which possesses both a TIR domain and a death domain – recruits a serine-threonine
kinase called IL-1-receptor-associated kinase (IRAK) via the death domains of each
molecule, and IRAK then becomes activated and associates with TRAF6. TRAF6
activation leads to NFκB activation and transcription of genes related to the inflammatory
process, such as TNFα, IL-6, and IL-12. TIRAP is also associated with MyD88 and in
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the case of a deficiency of either MyD88 or TIRAP, NFκB activation is delayed but still
occurs.119-122
The MyD88-independent pathway also utilizes TIRAP. Activation and
homodimerization of IRF-3 occurs via TIRAP after LPS stimulation, and it translocates
into the nucleus to switch on genes for IFNβ and other IRGs (interferon regulatory
genes). A third protein involved in LPS signaling is TRIF; it activates IRF-3 and is a very
potent activator of the IFNβ promoter. TRAM, about which less is known, does associate
with TIRAP and TRIF, but not with MyD88. According to TRAM-knockout mouse
studies, TRAM is essential to MyD88-independent LPS signaling via the TLR4
pathway.119-122
C4. Interleukin-4. IL-4 is a pleiotropic Type 1 cytokine produced by CD4+ T cells
(TH2), mast cells, basophils, and NK T cells (these express NK1.1); it has also been
reported to be produced by γδ T cells and eosinophils. T helper (TH) cells are a functional
subclass of T cells – TH1 cells help to generate cytotoxic T cells and TH2 cooperate with
B cells in the generation of antibody-mediated responses. Two major functions of IL-4
include differentiation of antigen-stimulated T cells (into TH2 type cells) and control of
the specificity of B cell immunoglobulin class switching (in mouse, to IgE and IgG1). IL4 also has a number of other functions in hematopoietic cells, including upregulation of
expression of MHC class II in B cells, upregulation of CD23, upregulation of the IL-4
receptor (IL-4R), and can act as a mitogen for B cell growth. In inflammation, it can also
act with TNF to induce expression of VCAM-1 (vascular adhesion molecule-1) on
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vascular endothelial cells and downregulates their expression of E-selectin (this is
thought to favor recruitment of T cells and eosinophils rather than granulocytes).125
The IL-4 receptor complex is made up of an α chain (IL-4Rα) and a γc chain; the
IL-4Rα binds IL-4 and the γc chain initiates clustering of the IL-4 receptors. The γc chain
is responsible for the initiation of the signaling pathway (Figure 4). IL-4 engagement
(crosslinking) of the IL-4R causes tyrosine phosphorylation of Jak (Janus family tyrosine
kinase) proteins, which then phosphorylate the IL-4Rα chain. Jak-1 associates with the
IL-4Rα chain, while Jak-3 associates with the γc chain. Once the IL-4Rα chain is
phosphorylated, sites for SH2- or PTB-domain-containing adaptor proteins become
available. There are three main signaling pathways: the IRS1/2 pathway, the Shc
pathway, and the STAT6 activation pathway.
The IL-4 phosphorylation substrate (4PS), also called IRS2 due to its high
homology with IRS1 (insulin receptor substrate), interacts with PI3K to initiate pathways
that lead to PKC and Akt activation and subsequent cell growth and survival. IL-4Rα
chain interaction with SH2-containing collagen-related protein (Shc) can lead to
activation of Grb2, Sos, and Ras/MAPK pathways, culminating in cell growth and
differentiation.
STAT6 activated by IL-4 is crucial for activation or enhanced expression of many
IL-4-responsive genes such as MHC class II, CD23, germline immunoglobulin ε (see Fig.
3) and γ1, and IL-4Rα chain. Upon IL-4 engagement, the IL-4Rα chain is phosphorylated
by the Jaks and STAT6 docks to the receptor via its SH2-domain. The receptorassociated kinases phosphorylate STAT6, which then disengages from the receptor,
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proceeds to form homodimers with other STAT6 proteins via their same SH2 domains,
and translocates to the nucleus. In the nucleus, STAT6 homodimers bind to consensus
STAT6 binding sites in IL-4-responsive genes to activate/enhance transcription.121
D. Immunoglobulin E. Immunoglobulin E (IgE) is one of five classes of antibodies. It is
involved in protective immunity only in cases of parasite invasion; worms and other
parasites are opsonized by IgE and IgG, leading to the further activation and recruitment
of eosinophils, macrophages, neutrophils, platelets, and the activation of complement. In
developed countries where national hygiene is promoted, there is little problem with
parasites. However, IgE can be produced in response to innocuous particles – an
unfortunate and exaggerated reaction called an allergic response. Normal individuals
have very small amounts (ng/ml) of IgE, as compared to IgG (μg/ml to mg/ml), and IgE
is elevated (particularly Ag-specific IgE) in allergic individuals. Both genetic and
environmental factors also play a role in any individual’s predisposition to allergic
disease. The most common allergic diseases include asthma, allergic rhinitis (hay fever),
atopic dermatitis, and food allergies. The most dangerous of the allergic reactions is
systemic anaphylaxis, which can be induced by any one of a number of antigens – such
as an insect sting. Allergies affect up to ⅓ of the population, and are therefore an
important disease state to be studied.
The IgE molecule is a member of the immunoglobulin family and is composed of
two light chains and two heavy chains. The light chains, either λ or κ, each contain a
constant and a variable domain, and the identical heavy chains (ε chain) have four
constant region domains and one variable domain. The antigen-binding specificity lies in
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the variable domains of the heavy and light chains, while the effector function and
isotype specificity are dictated by the heavy chain constant region.
E. Class Switch Recombination. When B cells class-switch (from IgM) to express IgE,
the first step is to synthesize germline Ig RNAs. These germline transcripts (Iε in this
case) are “sterile” because they do not code for proteins due to stop codons. However,
they do serve to initiate isotype switching. A recombination event (i.e., isotype switching
or class switching) then occurs wherein a downstream constant heavy-chain (CH) gene is
juxtaposed to the expressed V(D)J genes. V (variable), D (diversity), and J (joining)
regions make up the variable region of the heavy chain, and when the new CH gene joins
the V(D)J, the intervening sequences are deleted. The S (switch) region, which flanks
each CH gene, is the recognition sequence for the joining process during switch
recombination.126 These molecular events take place when the B cell has been activated
and is in secondary lymphoid tissue.
Regulation of isotype switching to IgE is dependent on cytokines and cell surface
molecules. Interleukin-4 (IL-4) and/or interleukin-13 (IL-13, human only), cytokines
secreted by T cells, mast cells, and basophils, are necessary but not sufficient for
induction of class switching; a second signal is required to switch to any isotype. This
second signal is CD40L, which is expressed by activated T cells responding to antigen.
This binds to CD40 on B cells and, together with IL-4, causes a signaling cascade that
results in ε germline RNA synthesis. Other cytokines and cell surface molecules have
been shown to affect IgE synthesis. Downregulation of IgE in vitro has been attributed to
interferon-α (IFNα), IFNγ, IL-8, IL-10, IL-12, and transforming growth factor β (TGFβ).
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Also, the interactions between sCD23-CD21 and CD28-B7 have been shown to increase
IgE production. The molecular regulation and modulation of IgE production are reviewed
in detail in

126

. IL-4 directs class switching to both IgG1 and IgE, but the second signal

can be a T-I (thymus-independent) antigen such as LPS or cell-contact-dependent signals
through cell-surface proteins such as the TCR (T Cell Receptor).
F. Plasma Cell Differentiation. After a B cell is mature (although naïve), it can
encounter its cognate antigen, usually within the context of the spleen or lymph node.
This interaction, along with CD4+ T cell help and follicular dendritic cells, leads to
germinal center formation, affinity maturation, and class switch recombination. The B
cells now differentiate into plasma cells and migrate to the bone marrow. The gene
expression profile of an activated germinal center B cell is significantly different than
that of the plasma cell (see Fig. 7). PAX5 (PAired box Protein 5; formerly called BSAP),
which can act as either a transcriptional activator or repressor, is required to maintain B
cell identity. PAX5 activates Activation-Induced cytidine Deaminase (AID), which plays
a vital role in class switch recombination, and represses the expression of X-box-binding
protein 1 (XBP1), the IgH, the IgL, and the J (joining) chain, all of which are important
for plasma cell development. While PAX5 must be repressed to induce plasma cell
formation, experiments have shown that loss of PAX5 is not sufficient to induce
expression of BLIMP1 (discussed below) or to induce plasma cell differentiation.127 A
key intermediate in CD40-mediated B cell activation is to apurinic/apyrimidinic
endonuclease 1 (APE-1) redox factor 1 (Ref-1). CD40 ligation leads to APE/Ref-1
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Figure 7. Plasma cell differentiation. The gene expression profile of a B cell
characterizes its identity: activated B cell or plasma cell. The key proteins and
transcription factors as well as the important known target genes are shown below. In the
text boxes, the gene expression programs are summarized. Theese transcription factors
regulate these genes either directly or indirectly. The transcription factors BCL-6, MTA3,
MITF, and PAX5 all repress plasma cell formation by repressing BLIMP1, XBP1, and
IRF4. When B cells begin the plasma cell development pathway, BLIMP1 represses the
B cell gene expression program. Mutual repression prevents activated B cells from
spontaneously progressing to the plasma cell stage and prevent plasma cells from
reverting to activated B cells. (Schematic is drawn with inspiration from Shapira-Shelef,
et al127)
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translocation from the cytoplasm to the nucleus, where it modulates PAX5 and early B
cell factor; importantly, this protein is crucial to CD40-mediated PAX5 activation.114
Microphthalmia-associated transcription factor (MITF) also inhibits plasma cell
formation by repression of interferon-regulatory factor 4 (IRF4) expression; loss of MITF
results in loss of the mature resting state and initiation of the plasma cell program.127
Another transcription factor, B-cell lymphoma 6 (BCL-6), is crucial to germinal
center formation, as it represses the expression of B lymphocyte-induced maturation
protein 1 (BLIMP1). BCL-6 performs this function by interfering with AP-1
transcriptional activators and also by binding a site within the BLIMP1 gene. MTA3
(metastasis-associated 1 family, member 3) interacts directly with BCL6 to repress
BLIMP1; loss of MTA3 leads to spontaneous expression of BLIMP1. Another important
repressor of plasma cell differentiation is BACH2 (BTB and CNC homology 1, basic
leucine-zipper transcription factor 2), although its mechanism of action has yet to be
defined.127
Plasma cell differentiation is driven by expression of several different
transcription factors. BLIMP-1, a transcriptional repressor, is required for plasma cell
formation and immunoglobulin secretion; it represses genes involved in cell cycle
progression and genes involved in maintenance of the identity of a mature GC B cell
(such as PAX5 and BCL-6), while inducing genes related to immunoglobulin secretion
pathways, such as IRF4. Repression of PAX5 leads to derepression of the IgH, IgL, J
chain, and XBP1 gene expression.127
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XBP1 is critical to plasma cell differentiation and acts downstream of BLIMP1 as
a regulator of the secretory phenotype in plasma cells. IRF4 is a transcriptional activator
whose role is not yet clearly delineated, but evidence indicates that it gives the “go
ahead” to the B cell for transition to plasma cell development by inducing the
proliferation necessary to do so. The exact mechanisms regulating the transition from
germinal center B cell to plasma cell are not known; generally, some factors must be
released from repression, and others must be downregulated or repressed.127 What is
known is briefly outlined above.
Immunoglubulin secretion is regulated by BLIMP1 and XBP1. BLIMP1 acts by
repressing PAX5 and thereby derepressing the transcription of IgH, IgL, and the J chain;
it also induces expression of IRF4 and OBF1 (octamer-binding transcription factor
(OCT)-binding factor 1), which function to activate various enhancers and promoters of
genes that encode proteins of the Ig chains. XBP1, whose mRNA is induced by activating
transcription factor 6 (ATF6) and is processed by inositol-requiring 1α (IRE1α), is
critical to the secretory program in plasma cells. It induces genes whose products are
involved in ER targeting and translocation, protein folding, protein degradation,
glycosylation of proteins, ER-to-Golgi trafficking, and targeting of Golgi vesicles to the
membrane. XBP1 also is involved in cell size and in increasing the size of the ER.127,128
For an overall picture of the events outlined above, please see Figure 6.
III. CD23 (FceRII), the low affinity IgE receptor.
A. Introduction to CD23. The two types of Fc receptors for IgE are called FcεRI and
FcεRII. FcεRI is a high affinity receptor that is involved in allergic mediator release. The
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other, FcεRII (CD23), is a low affinity receptor for IgE. CD23, first described by
Lawrence et al,129 is a natural regulator of IgE production.
B. Structure. FcεRII (CD23) (Fig. 8) is a member of the calcium-dependent (C-type)
lectin family,130 which require calcium for ligand (IgE) binding.131 Other proteins contain
this lectin “cassette”, including cell adhesion proteins (selectins).132 CD23 does not,
however, bind to IgE via a carbohydrate epitope133 like other members of this family,
such as the asialoglycoprotein receptor;134 instead, the lectin homology region contacts
the IgE. CD23 is a Type II integral membrane protein with an extracellular carboxyl
terminus. A series of repeat regions (3 in humans, 4 in mouse), composed of 21 amino
acids each, extend from the cell membrane to the lectin domain - the “stalk” region.
General differences between the human and mouse CD23 include a shorter C-terminal
region in mouse CD23 with loss of the inverted RGD sequence; mouse CD23 also has an
additional repeat region and an additional N-linked glycosylation site, both of which are
used.135 Gould et al136 found that the region of homologous repeats had a repetitive
heptad pattern similar to that of tropomyosin; this kind of pattern has a periodicity of
seven in the distribution of hydrophobic and hydrophilic residues. These structures are
predicted to form α-helical coiled-coils with two or three individual molecules interacting
with each other.137 This lab has obtained considerable evidence to support this model, and
the data indicates that receptor-receptor association is critical for ligand binding.
Crosslinking studies confirm that the stalk domains form oligomers and suggest that the
trimer is formed and binds IgE in a divalent manner involving two of the lectin heads
interacting with either symmetrical or non-symmetrical sites on IgE.
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Figure 8. Model for associated trimeric CD23. The stalk of the CD23 molecule forms a
coiled-coil structure. This would allow the lectin heads to interact in a divalent (or
trivalent) manner with IgE (published in Conrad, DH, et al. 138).
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CD23 breakdown can occur at the cell surface139 via cleavage by an
uncharacterized membrane-associated metalloprotease to release a monomeric 38Kd
(mouse) or 37Kd (human) molecule consisting of the carboxy-terminal portion of CD23
(soluble CD23 or sCD23). Further breakdown usually occurs due to the first fragment
remaining quite labile.135,140,141 In man, both fragments (37 and 25 Kd) have IgE-binding
capacity and the IgE interaction has been mapped to the lectin homology region of
CD23.141-143 The IgE-binding capacity of murine sCD23 is known to be a matter of
affinity and is related to the capacity of the receptor to self-associate. It is noteworthy that
mice transgenic for sCD23 displayed no changes in IgE responses, suggesting that the
associated form of CD23 is required for the regulation of IgE.
Cellular CD23 levels are known to be regulated by two different mechanisms. On
B cells, CD23 is protected from degradation while present on the cell surface; IgE does
not cause an increase in CD23 biosynthesis.144 The second mechanism is cytokinespecific upregulation. IL-4/STAT6 are very important in CD23 regulation, as seen in the
IL-4145 and STAT6146,147 knockouts – which had very low CD23 expression. IL-4,
however, has no effect on surface CD23, unlike IgE; rather, it increases the expression of
CD23 by increasing the levels of mRNA and protein.148
The genetic structure of the human and mouse CD23 is similar. A second isoform
of CD23 was discovered in man,149 and the two forms are called CD23a and CD23b (Fig
9). The second isoform (CD23b) is caused by an alternative transcription initiation site,
but the actual difference between the two isoforms is only the 6 amino-terminal amino
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Figure 9. The murine CD23a and CD23b promoter sequences. This details their
transcription factor binding sites and the placement of exons.
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CD23a
CAGATTCAGTCCACCACAGGTTTGATTCAGATCCAGGTTGTGTCATTTCCTTCCTTCTGCATTTTCAAGAGTTCTGA
C/EBP motif 1
STAT6 site
NFκB1 site
TTGGCATCGCTGACTCTCCAACAGTTTGCTTACCTGAGAAATAAAGGTAATAATAGCCCGGACTTCCCCAGGTTCTA
C/EBP motif 2
NFκΒ2 site
TATA box
GGGAGCACCAAAAAAGGCCTTGTGTGTGCTGTGGCCACCCAGGCGGTGAGCCCATAATTAGGTCTATAAAAATAGAA
Transcription start site
Exon 1
GCCATTAATGAACTGCTCACAGAAGACTACTGTCTTCAACACACTAGCCTGAGCTACCTTATCCAAGTGCTCCACAT
ATTCCAGAAGGAGAAGGACAGACTTCAAGTTCAAGTGAGTTTGTATTTATATGGGGCGNGGNNNNGAGANGGGGGCA
ACGGTATGGACAGAATCAAGAGGCATATGGGTCTCAGCTTCGGTCCTAAG

CD23b
Exon 2
AGGTAGTGCACGCCTCATCACTGAAAGGATCCAAACAAGACTGCCATGGAAGAAAATGAATACTCAGGTAGGAAGAT
NFκB site
TCCCAGGTGCCAATGCTGGCACTCATTTTGCTCAGGAGAGGGGGCGGCTCTTCAGTCCCTCTTTACCCAAGAGGGTG
STAT6 site
AATTCCCAAGAAGGGCCAGGAGGTAGAGTAGAGTGGGGGTTGAGCACTGACTGGCACCCGTGGCACACAGCCAGGTG
AAACAGGGAAATTCAAGGCCCCTCCTTTCTGTGACTCAACACCTTCCTAACAAAACTCAGCTCCAGCTGGACAGTTG
Mouse CD23b-specific exon
Exon 1b
GGAGTCAGATAGAGTTGAAAGCCAATTTGAACGGGAACTTGGAATTCAGAATGAATTCTCAAAACCAGGGTAAGGAA
GAACTGGGAACCTGCA

TA = missing 19 base pairs here, as compared to the human CD23b promoter
GA = missing 9 base pairs here, as compared to the human CD23b promoter
GA = missing 3 base pairs here, as compared to the human CD23b promoter
GG = missing 1 base pair here, as compared to the human CD23b promoter
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acids. CD23a is found on B cells and follicular dendritic cells. CD23b is widely
expressed on hematopoietic cells, including CD5+ B cells, T cells, monocytes,
eosinophils, platelets, Langerhan’s cells, and bone-marrow-derived mast cells.149 Both
human and mouse B cells constitutively express CD23a and it is upregulated by IL-4,
whereas CD23b (human) on any cell type requires IL-4 for expression.149-151 Until
recently, it was thought that only CD23a is found in the mouse;152 CD23b has lately been
found to be expressed and upregulated on murine intestinal epithelium in conditions of
food allergy.153 In addition, there are several CD23b isoform variants found in the mouse,
as depicted in Fig. 10; the Δ sign followed by a number indicates the lack of that exon.
These CD23b variant isoforms will be discussed in further detail in Part D (CD23b
Expression) in this section.
C. Function. CD23 plays a role in the regulation of IgE synthesis. Development
of transgenic mice in which the CD23 gene was deleted154-156 or animals that overexpress
CD23157 allowed examination of the role of CD23 in IgE production. One group reported
that CD23 knockouts had an enhanced IgE response,156 while other groups did not find
considerable differences in IgE responses to either parasite or antigen/alum
regimens;154,155 this lab also (data not shown) found IgE responses to be similar in
knockout and control mice. However, CD23 transgenic animals have a greatly reduced
IgE response in both parasite and antigen/alum regimens.
One finding with the use of anti-IgE is that basophils have a lower level of FcεRI
expression as a result of the lower serum levels of IgE,158 and this relates to the efficacy
of this treatment. CD23 is also a candidate for this type of therapy, and either the
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Figure 10. Pictoral view of the murine CD23 isoforms and isoform variants. This
shows the functional organization of the exons of the CD23 gene and the domains
encoded by the exons are noted along the top: TM = transmembrane domain, CC =
coiled-coil stalk domain, and IgE-BD = IgE-binding domain. As seen in the figure,
CD23bΔ5 lacks exon 5, CD23bΔ6 lacks exon 6, CD23bΔ5,6 laxk both exon5 and 6, and
CD23bΔ5,6,7 lacks exons 5-7. This occurs via mRNA splicing and affects the function of
CD23b. The last two gene constructs in this schematic are MCY and MTM, which are
CD23 constructs created for the purposes of research; MCY is full-length CD23 lacking
the sequence encoding the five N-terminal amino acids, while MTM is full-length CD23
minus the entire intracellular sequence except the last five amino acids. (Figure
Schematic reprinted from Montagnac, et al 160)
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membrane form or an engineered soluble form with full IgE-binding capacity may be
used. It is a self component and therefore no immune response could occur; in addition,
the close proximity of the interaction sites of CD23 and FcεRI159 also indicates that CD23
could not cause an anaphylactic reaction.
IgE production has been shown to be inhibited by anti-CD23 monoclonal
antibodies using both PBL (peripheral blood lymphocytes) from allergic patients and the
IgE-producing cell line U266.161,162 Anti-CD23 mediates suppression163 of mRNA for
secreted, but not membrane, IgE. With regard to sCD23, there was a modest potentiation
of IL-4-induced IgE production in the human in vitro system,164,165 but this lab was
unable to alter IgE synthesis using native sCD23 in mice. This lab has achieved IgE
modulation with intact CD23 in vitro and in vivo, using transgenic mice,166 culture in the
presence of CD23-transfected cells,167 and culture in the presence of LZ-CD23 (a trimeric
soluble CD23, created in this lab). A second function of CD23, due to endocytosed IgEantigen complexes, is enhanced antigen presentation in both humans and mice.168,169 This
lab has explored this area further using anti-CD23-antigen complexes and found
increased immunogenicity of these complexes.169
D. CD23b expression. As indicated earlier, the two isoforms are expressed on different
cell types, leading to a wide expression of the CD23b isoform in humans but none in
mouse (or so it was thought at the time that this project was begun). There were
hypotheses regarding the lack of murine CD23b expression; one was that there was a
defect in the transcription start site; the second was that perhaps murine lymphocytes
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simply do not express the CD23b isoform, while it was yet possible that other murine cell
types (other leukocytes or other cells) may express it under specific conditions.
Examination of the mouse CD23b sequence led to several observations. Kohler et
al
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used a luciferase reporter gene system to isolate the IL-4RE in the human CD23b

gene and went on to confirm by EMSA that an IL-4 induced protein did bind the
sequence. This lab conducted a computer-assisted homology search to find the
comparable sequence in mouse. EMSA analysis showed that the STAT6 site in the mouse
CD23b gene was fully functional. However, there was still little expression seen. Kondo
et al.171 showed by RT-PCR that the b isoform is produced, although at very low levels.
The conclusion was that the CD23b isoform was intact but still obviously unresponsive to
IL-4 stimulation. To examine the CD23b promoter in isolation, it was cloned into a
luciferase vector and evaluated in vitro for upregulation by IL-4. The murine CD23b
promoter region has a (functional) STAT6 site that allows for IL-4 inducibility; there is
also an NFκB site 38 bp upstream of the STAT6 site. This same orientation occurs in the
human CD23b promoter, and the two sites are 36 bp apart. However, the human and
mouse CD23a promoters have their transcription factor (TF) binding sites in opposite
orientation, with only 18 bp between them.
Initially, studies in this lab analyzed the mouse CD23b promoter (murine CD23b:
283 bp, from –239 to +44) as compared to the human CD23b (hCD23b) promoter, and
the murine version of the promoter had three regions "deleted" (see Figure 8). None of
the deletions correspond to any known TF binding sites when compared to the human
CD23b promoter region; namely, STAT 6 and NFκB.
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The mouse CD23b (mCD23b) promoter was corrected for two of the defects,
alone and in combination. The reporter (luciferase) plasmids were transfected into
M12.4.5 cells (a murine B cell line) and cultured in the presence and absence of IL-4.
Replacement of the 19-bp deletion or restoration of the NFκB site to consensus alone or
in combination had no effect on the efficiency of the CD23b promoter. Also note that
isolation of the CD23b promoter from any possible negatively influencing sequences had
no effect upon its inducibility by IL-4.
Since the mCD23b promoter seemed to be intact, this same reporter vector
containing the murine CD23b promoter was transfected into the RPMI 8866 human B
cell line; this was to determine if the mouse was simply lacking a factor required for
CD23b expression. There was no increase in luciferase production by these cells when
they were induced by human IL-4. Two other human cell lines were also transiently
transfected with similar results. Reciprocal experiments were also performed; the human
CD23b promoter in a luciferase vector was transiently transfected into the M12.4.5
murine B cell line. No luciferase expression was observed.
This led to the “faulty transcription initiation hypothesis”, in which the defect in
the mCD23b promoter is in transcription initiation. This is supported by the fact that
neither replacement of the 19-bp deletion at +6 nor consensus matching of the NFκB site
can explain the lack of mCD23b expression. Additionally, in the mCD23b promoter
region, there is a cluster of putative TF binding sites for several proteins; these may
inhibit transcription initiation efficiency by blocking the interaction of RNA polymerase
with the DNA. It is also not known if CD23a can “sequester” transcription factors away
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from CD23b. This cluster is not found in the hCD23b promoter region. Also, mouse
CD23b does not upregulate in either mouse or human cell lines – further evidence that
transcription cannot be initiated from the CD23b promoter.
Since the work described above was done, Ewart, et al,172 showed that the CD23a
promoter is only sensitive to IL-4 when the STAT6 site most distal to the transcription
initiation site is available; and that the CD23b promoter is responsive to IL-4, CD40L,
and is variably responsive to anti-μ stimulation.172
The second hypothesis for the lack of CD23b expression was that mice just may
not express high levels of CD23b in their lymphocytes, which are the cells in which we
would expect to find the protein. Lymphocyte cell lines have typically been chosen for
experiments based on that assumption. Instead, murine CD23b (mCD23b) has been found
to be expressed in intestinal epithelial cells.153 This alone suggests that the regulation of
murine CD23b may be very different from the human system.
A collaborator found mCD23b expression153 on intestinal epithelial cells when the
individual had food allergies. Briefly, after ingestion of food antigen, local GI symptoms
develop, such as vomiting, nausea, and diarrhea; extraintestinal symptoms may occur in
the skin and airways.173 In severe cases, systemic anaphylaxis may occur.173-175 It is
interesting to note that increased levels of CD23 have been found in individuals with food
allergy, inflammatory bowel disease,176 and in the airways of asthmatics.177 CD23
appears to be expressed constitutively at extremely low levels on the apical membrane of
murine intestinal epithelial cells,153 and is dramatically upregulated in sensitized mice.153
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An understanding of the physiology of food allergy is crucial to understanding the
role of CD23 in this disease. Mast cells, the effectors of the symptoms of an allergic
reaction, are beneath the lamina propria of the gut and should therefore be masked from
antigen contact.178 There are two phases of antigen penetration in hypersensitivity
reactions. In phase I, most ingested proteins are digested by enzymes anchored in the
enterocyte microvillus membrane prior to transcytosis, but a few proteins are taken up
into endosomes and transported across the cells. Most of these fuse with lysosomes and
are digested before reaching the basal epithelial cell membrane and gaining access to the
lamina propria and the circulatory system. This process is relatively slow, usually taking
20-30 minutes.179 However, a food antigen is specifically and rapidly taken up by the
intestinal epithelial cells as intact protein. Uptake of the food antigen and transepithelial
protein transport occurs within 3 minutes after exposure to antigen in the sensitized
animal, as has been shown in rats sensitized to HRP.180,181 Phase I was shown to be IgEdependent (intestinal epithelial cell dependent) but mast cell independent and is specific
for the sensitizing antigen.180-182 In phase II, mast cells are activated >30 min. later via
IgE-ag complexes cross-linking the FcεRI and degranulation occurs. GI symptoms, such
as altered intestinal epithelial cell ion transport, which can result in diarrhea and other
unpleasant GI tract effects, ensue following mast cell degranulation.
It has been shown that CD23 and IgE can enhance intestinal transepithelial
antigen transport in sensitive rats.181 Antigen uptake at the level of the intestinal
epithelium was found to be specific; HRP-sensitive rats had allergic reactions to HRP but
not ovalbumin.180 IgE is required for sensitization: whole serum, but not IgE-depleted

55
serum, could transfer sensitivity into naive rats and, additionally, the sensitization was
specific.183 Enhanced expression of CD23 in sensitized rats was shown to be present on
the apical surface of the intestinal epithelial cell membrane by immunogold labeling; 3
min. after challenge, these same cells had a sharp decrease in membrane-expressed CD23
but a concurrent increase in CD23 in the endosomes of these cells.153 The involvement of
CD23 in the state of sensitization of the animal was further supported by the inhibition of
antigen transport and the hypersensitivity reaction in CD23-/- mice.183
There is evidence153 that CD23b is the protein isoform involved in the sensitized
murine system. Yu, et al. examined the role of CD23 in enterocyte (intestinal epithelial
cell) uptake and transport. Gut epithelial CD23, shown by immunohistochemical staining
and immunogold labeling to be present on the apical membrane of the jejunal epithelial
cells, is involved in the uptake and transport of antigen in sensitized IL-4+/+ mice but not
in sensitized IL-4-/- mice, suggesting that IL-4 is involved in the regulation of CD23
expression in intestinal epithelial cells.183 Importantly, CD23-/- mice were found to lack
antigen transport.183,184 In addition, cultured intestinal epithelial cells (IEC4.1 cells) were
shown by RT-PCR (Reverse-Transcriptase PCR) to be expressing only CD23b
transcript.153 Yu et al153 also showed that intestinal epithelium can and does express
CD23b transcript; indeed, as shown in a couple more recent reports, there are several
different splice forms of CD23b (Fig. 10) that can be found in intestinal epithelium.
Classical CD23b is the predominant form expressed, but CD23bΔ5 is the next most
prevalent, while CD23bΔ6, Δ5,6 and Δ5,6,7 are found only in very tiny amounts.185
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CD23bΔ5 was found to bind to IgE with the typical biphasic affinity as the
classical CD23b form, whereas CD23bΔ6 did not bind IgE at all185 – apparently the
coiled-coil stalk is necessary for optimal IgE binding. CD23bΔ5 is induced in vitro by IL4 and in vivo by sensitization to a food allergen.153,186 This CD23b-derived splice form is
constitutively internalized153 and is the form which mediates the apical to basolateral
transport of free IgE and IgE/allergen complexes. Classical CD23b can only bind
IgE/allergen complexes, but not free IgE, for transcytoplasmic transport. The
physiological function of free IgE binding by CD23bΔ5 may be the recycling/clearance
of luminal IgE. In both cases, the IgE or IgE/allergen complex was “protected” from
degradation during CD23-dependent transport across the cell in sensitized mice.185
However, a related problem, that of basolateral-to-apical transport of IgE to the lumen of
the intestine, has yet to be observed and the mechanism remains elusive.
Interestingly, in the human, both CD23a and CD23b are co-expressed in intestinal
epithelial cells.160 CD23a is found in the basolateral surface and CD23b is found at the
apical surface. This is quite opposite the situation in mouse, where CD23b is the
exclusive isoform. mRNA for human intestinal epithelial CD23 was also cloned and
tested for the presence of a bΔ5-like product, but none was found. Only full-length stalk
region was found in all clones tested.160 CD23a is effectively internalized by CCPs and
bears a cytoplasmic tyrosine-6 (encoded in the CD23a-specific exon) which is found to
be in the classical consensus sequence for a tyrosine-based, clathrin-dependent signal for
internalization.
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The internalization mechanism of CD23b and its splice forms was discovered to
be CCPs (clathrin-coated pits), and the absence of exon 5 in CD23bΔ5 caused this variant
to be constitutively internalized. Data from anti-CD23/transferrin-internalization colocalization experiments with the CD23b Δ5, Δ6, Δ5,6 and Δ5,6,7 indicates that
endocytosis of CD23 isoforms is strongly related to the stalk region of CD23 (less stalk =
more efficient endocytosis).160 Montagnac, et al,160 suggests first that the CD23b-specific
exon negatively regulates the endocytosis signal and, further, that the modulatory
function of the CD23b-specific exon is under control of the stalk region. Evidence comes
from the CD23bΔ5, wherein a deletion of the stalk allows for constitutive internalization,
which has CD23b-type intracytoplasmic region. This is very different from the scenario
in human CD23, and as more data is gathered, underscores the suggestion that human and
mouse CD23 (and its isoforms) is regulated very differently.

IV. Research Objectives.
A. Effects of anti-CD44 on B cell Growth and Differentiation. Prior to the beginning
of this project, an anti-CD44 mAb created in this lab (and named RK3G9) was found to
inhibit IgE production by murine B cells when coated on a culture plate. The present
study focused on the effects of CD44 cross-linking on murine B cell activation and
differentiation in vitro, to begin to elucidate the role of CD44 in B cell maturation. This
study demonstrates that CD44 cross-linking via anti-CD44 mAb inhibits B cell
proliferation and affects antibody production. Following CD44 cross-linking, B cells
acquire a fibroblast-like morphology and do not cluster. In addition, CD44 cross-linking
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inhibits B cells stimulated via the CD40L or LPS signaling pathways, but not by BCR
stimulation. This indicates that the CD44 cross-linking effects have some specificity and
suggests that CD44 cross-linking could control polyclonal B cell activation by CD40L,
but allow sIgM/CD40L activation to continue. In addition, the formation of plasma cells
is decreased.
B. CD23b Promoter Defect: to B or not to B. This project was begun – and finished prior to much of the information just given in the Introduction Section. However, in the
early stages of this project, the main objective was to correct the CD23b promoter
“defect” by various combinations of the mouse CD23a and CD23b promoters. Human
CD23b was also compared to mouse CD23b and these promoters were also to be
combined. Human CD23b is known to be expressed on a wide variety of hematopoetic
cells and these studies would allow determination of whether the two species regulate this
important molecule in entirely different or very similar manners. With the discovery of
CD23b on enterocytes, this project objective changed: to discover what regulates CD23b
expression – as it differs considerably from that of CD23a – in the murine system. The
elucidation of the regulatory apparatus would no doubt be an important step in the fight
to eradicate food allergy.
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MATERIALS AND METHODS
I.

Anti-CD44 project.

A. Animals and Media.

Female Balb/c mice were purchased from The Jackson

Laboratory (Bar Harbor, ME) and were housed in accredited animal facilities. All mice
used in experiments were between 6 and 14 weeks of age. The medium used consisted of
RPMI 1640 supplemented with 10% heat-inactivated FBS (Hyclone, Logan, UT), 2 mM
glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 100 U/ml
penicillin, 100 U/ml streptomycin (all from Life Technologies, Rockville, MD), 10 mM
HEPES buffer, and 5 X 10-5 M 2-mercaptoethanol (Sigma, St Louis, MO), referred to as
“B cell medium”.
B. B cell isolation and growth conditions. B220+ B cells (>95%) were isolated from
disrupted spleens by staining with PE-anti-B220 (Becton Dickinson, Los Angeles, CA) or
FITC-anti-B220 and sorting using a MoFlo cytometer (Dako-cytomation, Ft Collins,
CO). B cells were plated at various concentrations in 96-well plates (Costar, Cambridge,
MA) in a volume of 200 μl of B cell medium and stimulated with 50,000 U/ml
interleukin-4 (IL-4), 5 ng/ml IL-5, 0.01 μg/ml CD40 ligand trimer (CD40LT), and 0.1
μg/ml mouse IgG1 anti-trimer (M15), collectively referred to as “Activation Cocktail”, at
37°C in a 5% CO2 incubator. These activation conditions have previously been shown to
be optimal for IgE production.167 Plates were coated with 50 μl of 10 μg/ml of RK3G9
(anti-CD44, rat IgG2a187), IM7 (anti-CD44, Pharmingen, San Diego, CA), or C0H2 (rat
IgG2a isotype control) and blocked with 2% FBS in PBS, prior to plating cells.
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C. B cell proliferation. On day 3 post-culture, the B cells were pulsed using 1μCi
[3H]thymidine (ICN Biomedicals, Costa Mesa, CA)/well for 6 hrs. Cells were then
harvested onto a Unifilter 96 plate (Packard Instruments, Meriden, CT) using a Filtermate
196 plate harvester (Packard), and the incorporation of [3H]thymidine into DNA was
measured by reading the plate in a model 9902 TopCount (Packard).
D. ELISAs. On day 8 post-culture, levels of IgE, IgG1, IgM, or IgG2a in supernatants
were determined by ELISA as described previously

166

. Briefly, a pair of rat anti-mouse

IgE monoclonals, B1E3 (5 μg/ml) and biotinylated R1E4, were used as the capture and
biotinylated secondary antibody, respectively. Biotin was then recognized by streptavidin
coupled to alkaline phosphatase (Southern Biotechnology Associates, Birmingham, AL).
Total IgG1 was determined by using an unlabeled primary goat anti-mouse Ab at 5 μg/ml
and detected with goat anti-mouse class-specific Ab coupled to alkaline phosphatase (all
Abs are from Southern Biotechnology Associates). Total IgM and IgG2a were determined
similarly; the primary Ab was unlabeled goat anti-mouse IgG2a or IgM, and the detection
Ab was alkaline-phosphatase-coupled goat anti-mouse IgG2a or IgM.
E. Elispot. On the appropriate day, B cells were removed from 96-well plates via
Trypsin-EDTA (due to the RK3G9-mediated spreading and binding to the plates),
counted, and plated (in 150 μl) onto a PVDF-membrane Elispot plate (Multiscreen-HTS,
from Millipore, Bedford, MA) at a concentration of 50K in the 1st well, with dilutions of
1:2 all the way through well 11. The plates were pre-coated with B1E3 (see details in
ELISA section) or anti-IgG1 at 10 μg/ml in 100 μl/well overnight at 4°C prior to B cell
plating. The cells were then allowed 16-20 hours to bind to the plate at 37°C (+ 5% CO2).
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After incubation, the Elispot plate is washed with filtered PBS + 0.1% Tween 20 five
times, with two of the washes having a 5-minute soak at room temperature. The primary
antibody, biotinylated R1E4 (in the case of an IgE Elispot), is added (at a 1:500 dilution
in 100 μl/well) to the plates in PBS and incubated for 1 hour at 37°C. The plate is then
washed as described above and streptavidin-AP (at a 1:250 dilution in 100 μl/well) (or
IgG1-AP in the case of an IgG1 elispot) is added to the plates for 1 hour at 37°C. The
plate is washed as described previously and substrate (AMP buffer + 1 mg/ml BCIP) is
added for 5 minutes at room temperature in the dark. The plate is then washed with DI
water on both sides and allowed to dry before counting. Counting was done on a stereo
microscope.
F. FACS. Cells were washed and stained with PE-conjugated anti-CD38 in PBS/1% FBS
on ice for 30 minutes. They were then washed once more prior to reading in the FC500
flow cytometer (Beckman-Coulter, Fullerton, CA).
G. Steptavidin-microbeads cross-linking experiments. For the cross-linking of
biotinylated RK3G9: 100 μl streptavidin microbeads (Miltenyi Biotec, Auburn, CA)
were pre-mixed with 100 μg of biotinylated RK3G9 and incubated on ice for 30 min.,
washed in PBS three times, resuspended in media, and added to the cell cultures. For the
cross-linking of unlabeled RK3G9 with biotinylated MAR18: 100 μl streptavidin beads
were pre-mixed with 200 μg biotinylated MAR18, incubated on ice for 30 min., washed
in PBS three times, resuspended in media, and added to the cell cultures in conjunction
with 1 or 10 μg of RK3G9.
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H. In vivo RK3G9 experiment. Male Balbc/J mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were housed in accredited animal facilities. These mice
were 6 weeks of age. Alum-Ag injections consisted of 4 mg/mouse Alum (Pierce,
Rockford, IL) + 100 μg/mouse KLH-DNP (San Diego, CA) + PBS. Each mouse was
injected with 200μl Alum-Ag intraperitoneally (i.p.) on days 0 and 7. The RK3G9
injection consisted of 1 mg/mouse in PBS and was given subcutaneously (s.c.) on days 2, 0, and 7.
The blood was taken by a capillary tube held to a tail vein nick. 200-400 μl of
blood was collected from each mouse. This blood was then put on ice for one hour and
then centrifuged at 10,000 rpm for 5 min. The supernatant (serum minus blood cells) was
collected and used in an IgE ELISA, which was performed as described above.
II. CD23b Promoter Project.
A. Cell Lines. Cell lines used were the M12.4.5 (mouse B cell, ATCC), HEK293 (human
epithelial kidney cells, ATCC) and IEC4.1 (mouse intestinal epithelial cells, courtesy of
Mary Perdue, Intestinal Disease Reasearch Programme, McMaster University, Hamilton,
Ontario, Canada).
B. Plasmids. The firefly luciferase vectors pGL3-Basic, pGL3-promoter, and pRL-TK
(Renilla luciferase) were purchased from Promega (Madison, WI). The luciferase vector
pLUC+ and the construct pLUC+CD23b were generously provided by Ioana Visan and
Christian Kneitz (Medizinische Poliklinik, University of Würzburg, Würzburg,
Germany). The TA cloning vectors pCR2.1 and pCR3.1-Uni were purchased from
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Invitrogen (Carlsbad, CA). The four pCR3.1 CD23b constructs were generously provided
by Alexandre Benmerah (Institut National de la Santé et de la Recherche Médicale).
1. pGL3-CD23bProm-TATA construct. Previous work in this lab had been done with
the CD23a and CD23b promoters in the pGL3 vector. To begin the process, the pCR2.1CD23bProm construct was used, described as follows: first, an NcoI site was added to the
CD23b promoter region (5’-AAAGCCAATTTGAACCCATGGCCGAATTCTGCAG3’, NcoI site in bold, underlined A to be deleted, underlined G to be mutated to A) via
Quikchange Site-Directed Mutagenesis (Stratagene, La Jolla, CA) by PCR. The oligo
sequences are listed in Table 1, primer set #1. After the Quikchange, the resulting product
was transformed into XL1-Blue Supercompetent Cells and the plasmid DNA was isolated
by miniprep (Promega). The mutation was confirmed by restriction enzyme digest
(MscI). The CD23bProm fragment was amplified by PCR (Table 1, primer set #2) and
cut to fit its vector by MscI and Acc65 I. The PCR protocol was 35 cycles of the
following: 94°C for 1 min., 55°C for 1 min., 72°C for 2 min. This was followed by a final
cycle at 72° for 6 min. Meanwhile, the pGL3 vector containing CD23a (pGL3-CD23a)
was digested by restriction enzymes (MscI and Acc65 I) to remove the entire CD23a
promoter except for its TATA box. The CD23bProm insert was then ligated into the
pGL3 vector containing the CD23a promoter TATA box, creating a construct comprised
of CD23b promoter plus CD23a TATA box, called pGL3-CD23bProm-TATA. Ligation
was confirmed by digest with Ava I. This was subsequently confirmed to be in the correct
orientation by sequencing (VCU DNA Core Lab) with the Promega primers RVPrimer3
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Table 1. This table lists the oligos used in the construction of various CD23 plasmids.
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Table I. Oligos used in construction of CD23b constructs
1. pCR2.1CD23bProm –
added NcoI site
2. Primers used to
amplify the
~300bp
CD23bProm
3. Promega
primers
4. CD23 fulllength primer
5. CD23 isoform
specific primers
6. Dr. Benmerah’s
Full-length CD23
oligos

sense: GAA AGC CAA TTT GAA CCC TGG CCA AAT TCT
GCA GAT ATC
antisense: GAT ATC TGC AGA ATT TGG CCA GGG TTC AAA
TTG GCT TTC
sense: AGG GTA CCG AGC TCG GAT CCA CTA G (covers
Acc65 I site)
antisense: AGG GTG GCC AGG GTT CAA ATT GGC (covers
MscI site)
RVPrimer3: CTA GCA AAA TAG GCT GTC CC
GLPrimer2: CTT TAT GTT TTT GGC GTC TTC CA
End-1: GCA GAA CTG GTA CGT ATG GAA GAT CC
End-2: CGA GAT CCA TTG TGA GCA GAA GTT TG
(used in conjunction with either the α or β primer, in row #5)
α: CCT CAT CAC TGA AAG GAT CCA AAC AAG
β: GAA AGC CAA TTT GAA CGG GAA CTT GG
ε: GGA GCC CTT GCC AAA ATA GTA GCA C
Oligo B: ATG AAT TCT CAA AAC CAG GGA
Oligo F: TCA GGG TTC ACT TTT TGG G
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and GLPrimer2 (Table 1, #3), which are specifically created for sequencing pGL3 and
pLUC+ luciferase vectors.
2. CD23a and CD23b full-length clones to test serum potentially containing
specific anti-CD23a or anti-CD23b antibodies. The cell line used for RNA in these
experiments was M12.4.5 cells. These were stimulated with IL-4 and grown for 48 hrs.
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). The primers used in RTPCR are detailed in Table 1, #4. The RT-PCR kit used was Perkin Elmer Gene Amp PCR
system 2400 (Applied Biosystems, Foster City, CA). The RT (reverse transcriptase) step
consisted of the addition of 19 μl of a “MasterMix” (10x PCR buffer, DEPC dH2O, 25
mM MgCl2, 1 mM of each dNTP, 2.5 μM random hexamer primers (in the case of
CD23b) or “End-2” oligo (in the case of CD23a) (Table 1, Row #4), 20 U RNase
inhibitor, and 50 U muLVRT) to 1 μg of sample RNA. The cycling parameters were as
follows: 25°C for 10 min., 42°C for 15 min., and 95°C for 5 min.
a) CD23a: The cell line used was M12.4.5 cells. The PCR portion consisted of 20
μl RT product, 25 mM MgCl2, 10x PCR buffer, 0.5 μl DNA polymerase, and the
remaining volume up to 100 μl is DEPC dH2O. The PCR cycling parameters were 94°C
for 1 min., 55°C for 1 min., and 72°C for 1 min. 30 sec. This was repeated 49 times and
finished with 72°C for 8 minutes. Primers used in PCR were the “End-1” and the α oligo.
The PCR product was run on a 1% TBE gel to verify size, then the PCR reaction was
ligated directly into pCR2.1 plasmid. This was transformed into XL1-Blue
supercompetent cells (Stratagene), and the presence of the 612 base-pair CD23a clone
was confirmed by EcoRI restriction enzyme digestion. This was sent to the VCU DNA
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Core Lab for sequencing (T7 primers) and was shown to be both the correct sequence and
in the correct orientation. This plasmid was called pCR2.1-CD23a-α2ε (full-length
CD23a).
b) CD23b: The PCR portion consisted of 20 μl RT product, 25 mM MgCl2, 10x
PCR buffer, 0.5 μl DNA polymerase, and the remaining volume up to 100 μl is DEPC
dH2O. The PCR cycling parameters were 94°C for 3 min. (only once), then 94° for 30
sec., 58°C for 30 sec., and 72°C for 30 sec, done in all a for a total of 35 cycles, followed
by 72°C for 5 min. Oligos used were “Oligo B” (with phosphate added) and “Oligo F”.
The ~1 Kb product was then cloned into pCR3.1-Uni (where the added phosphate on the
Oligo B caused the CD23b DNA to insert in the correct orientation) and transformed into
XL1-Blue supercompetent cells (Stratagene). The presence of the CD23b clone was
confirmed by EcoRI and HindIII restriction enzyme digestion. The sequence was
confirmed by sequencing (VCU DNA Core Lab). The plasmid was called pCR3.1CD23bFL (FL = Full Length).
The pCR3.1-CD23bFL was also put into the pEF4 vector. The CD23bFL was cut
from pCR3.1-CD23bFL by sequential Nhe I and Not I digestion; the CD23bFL fragment
was blunt-ended by the Klenow procedure prior to the second enzyme digestion. The
pEF4 vector was cut by sequential digestion with EcoRV and Not I. The appropriate
fragments were ligated, transformed into XL-1 Blue cells as usual, plasmid DNA
isolated, and ligation was confirmed by digestion with BamHI. This product (pEF4CD23bFL) was sequenced at the VCU DNA Core Lab and found to be correct.
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3. Other CD23b constructs. Four CD23b constructs were very generously
provided by Dr. Alexandre Benmerah. These were pCR3.1-CD23b∆5, pCR3.1CD23b∆6, pCR3.1-CD23b-MCY’, and pCR3.1-CD23b-MTM. These plasmids (see
Figure 11) are defined as follows:
a) pCR3.1-CD23b∆5: full-length CD23, minus exon 5
b) pCR3.1-CD23b∆6: full-length CD23, minus exon 6
c) pCR3.1-CD23b-MCY’: full-length CD23, but lacks the sequence encoding the
five N-terminal amino acids
d) pCR3.1-CD23b-MTM: full-length CD23, but lacks the entire intracellular
sequence EXCEPT for the sequence encoding the five N-terminal amino acids
C. Transfection of cell lines.
1. Electroporation. Log phase cells were washed in PBS, resuspended in EB
(Electroporation Buffer, composed of appropriate media for cells + 10% FBS + 10mM
HEPES), and brought to a concentration of 4 x 107 cells/ml. Added to each 0.4mm
electroporation cuvette was 200 μl of cells and either 20 μg of the “test” DNA or the
control plasmid at a 1:50 ratio. When the Dual Luciferase Assay was performed, an
additional control plasmid (pRL-TK) was added at either a 1:50 or 1:100 ratio.
Electroporation parameters were 250 V, 950 F, with only 1 pulse; electroporation
constants were recorded. Pulsed cells were incubated on ice for 10 min. prior to being
added to 60mm cell culture dishes (50 μl/dish) containing 10 ml of appropriate media or
EB +/- stimulation. Cells were grown for 48 hrs at 37°C, 5% CO2.
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Figure 11. The schematic of the CD23b coding regions from the four pCR3.1-CD23b
constructs provided by Dr. Alexandre Benmerah.
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2. FuGene Transfection. Fugene 6 Transfection Reagent (Roche Molecular
Biochemicals, Indianapolis, IN) is a multi-component lipid-based transfection reagent
that complexes with and transports DNA into the cell during transfection. The basic
protocol is to add FuGene reagent + DNA to log phase cells. For more detailed
information, go to http://biochem.roche.com\pack-insert\1814443a.pdf.
D. Luciferase Assay Protocol. At the appropriate time-point, harvest cells and wash
with PBS 2x. Resuspend pelleted cells in 250 μl Cell Lysis Buffer to lyse cells (provided
with the Promega Luciferase Assay kit) for 15 min. at room temperature. Lysates may be
frozen down at -70°C or read immediately. These lysates were analyzed in a Monolight
2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA).
E. RT-PCR for CD23b in IEC4.1 cells. RT-PCR was used to confirm the presence of
CD23b mRNA in the IEC4.1 cells. The RT (reverse transcriptase) step consisted of the
addition of 19μl of a “MasterMix” (10x PCR buffer, DEPC dH2O, 25 mM MgCl2, 1 mM
of each dNTP, 2.5 μM random hexamer primers, 20 U RNase inhibitor, and 50 U
muLVRT) to 1 μg of sample RNA. The RT cycling parameters were as follows: 25°C for
10 min., 42°C for 15 min., and 95°C for 5 min. The PCR portion of the IEC4.1 CD23b
experiment consisted of 20 μl RT product, 25 mM MgCl2, 10x PCR buffer, 0.5 μl DNA
polymerase, and the remaining volume up to 100 μl is DEPC dH2O. The PCR cycling
parameters were 94°C for 3 min., followed by 94°C for 1 min. 30 sec., 60°C for 2 min.,
and 72°C for 3 min. Steps 2-4 were repeated 34 times and finished with 72°C for 7
minutes. The RT-PCR results were analyzed by DNA electrophoresis on a 1% TBE gel.
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RESULTS
I. Results of investigation of effects of anti-CD44 on B cell activation and
differentiation.
A. Immobilized anti-CD44 Abs inhibit B cell proliferation. The goal of this study was
to examine the role of CD44 cross-linking via immobilized anti-CD44 antibody in B cell
activation and/or differentiation. The cell culture plates used were chosen for high
protein-binding capacity (Costar #3370). Both RK3G9 and IM7 are anti-CD44
antibodies. The monoclonal anti-CD44 (RK3G9) was made in this lab; IM7 is a
commercially available mAb. 2H10 is a mAb directed against CD23, and is used in this
context as a specific control. C0H2 is a non-specific rat IgG antibody used as a nonspecific isotype control. 96-well Costar plates were coated with RK3G9, IM7, 2H10, or
C0H2. The stimulation used was Il-4, CD40LT, M15, and IL-5 (as detailed in the
Material & Methods section). Freshly isolated B cells (>94% B220+) were then grown for
three days on these immobilized anti-CD44 or control Abs and were assayed for
proliferation by [3H]-thymidine incorporation. The proliferation of the cells grown on
both anti-CD44 Abs was significantly reduced, as compared to the two controls, across
the entire range of B cell concentrations used (Figure 12A). Having established that
C0H2 and 2H10 both have no effect on the B cells, C0H2 was chosen as a single control
for the remainder of the experiments.
It is interesting that the RK3G9-treated cells displayed a spread phenotype (Fig
12C, panel B), while C0H2-treated cells had a round cell shape and clustering (Fig 12C,
Panel A), which is normal for B cell cultures. However, this spread phenotype has been
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Figure 12. B cell proliferation is greatly reduced due to CD44 cross-linking by
immobilized anti-CD44 antibody. A, Immobilized anti-CD44 (RK3G9 or IM7) causes
greatly reduced proliferation, as compared to control antibodies 2H10 or C0H2, of B
cells grown for 3 days in culture. B, Soluble RK3G9 or C0H2, at a concentration of
100 mg/ml, was added to B cell cultures. Proliferation was not affected by soluble
RK3G9. These data are representative of at least three separate experiments.
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In order to determine whether immobilization of the anti-CD44 antibody is
critical to its ability to inhibit proliferation, soluble RK3G9 or C0H2 antibody was added
to B cell cultures. The results showed that soluble RK3G9 had no effect on the
proliferation of the B cells, as compared to control cells (Fig. 12B). Reduction of B cell
proliferation could be attributed to increased apoptosis, as it is known that signaling via
CD44 can promote apoptosis.19,24,25,31 However, CD44 cross-linking did not promote
increased B cell apoptosis, as measured by the TUNEL assay (data not shown).
The possibility that RK3G9 could also cause inhibition of T cell responses was
tested, since T cells have been shown to interact with many anti-CD44 antibodies. The T
cells were tested with a non-specific activator (Concavalin A) or a specific activator
(anti-CD3). Examination of the proliferation of the T cells revealed that, in both cases,
there was no reduction in growth due to the presence of the anti-CD44 antibody RK3G9
(Fig. 13).
B. Ig production is inhibited by CD44 cross-linking on B cells. We next examined Ig
production to further assess the inhibitory activity of immobilized RK3G9. In view of the
fact that IgE production in vitro is known to require a high cell division level,115,188 we
chose to examine the ability of the B cells to produce IgE when cultured on immobilized
anti-CD44. We have also shown that the amount of IgE produced is higher when
relatively low numbers of B cells are cultured using our protocol,189 again due to
increased B cell proliferation.115,188 Plates were coated with RK3G9, IM7, or C0H2, and
purified B cells were grown for 8 days in the presence of the Activation Cocktail (see
Materials & Methods). Secreted IgE was assayed by ELISA on day 8. B cells incubated
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Figure 13. CD44 crosslinking on T cells via anti-CD44 antibodies causes no decrease in
their ability to proliferate. A, T cells grown on immobilized RK3G9 or control had similar
levels of proliferation. These were stimulated with the mitogen ConcavalinA. B, The T
cells had no decrease in proliferation capacity, as evidenced by

3

H-thymidine

incorporation, when grown on RK3G9 or control when specifically stimulated by the
anti-CD3 antibody 2C11. 2C11 was coated onto the plate concomitantly with RK3G9 or
C0H2, or plated alone as a positive control; RK3G9 and C0H2 were also coated alone as
negative (no stimulation) controls. There was no difference between any of the cultures
which had contact with the anti-CD3, regardless of anti-CD44 presence or not.
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Figure 14. CD44 crosslinking via anti-CD44 antibodies on B cells causes a decrease
in their ability to produce immunoglobulins. A, B cells grown on immobilized
RK3G9 or IM7 produced dramatically reduced quantities of IgE, in comparison to the
control (C0H2). B, When the IgE production is plotted as IgE produced per input B
cell, the IgE production is shown to be incredibly inhibited. C, IgG1 production
(μg/input cell) is significantly inhibited by immobilized anti-CD44. D, IgM
production is massively inhibited by immobilized anti-CD44, shown as μg IgM/input
cell. E, B cell cultures were also stimulated with LPS (25 μg/ml) + IFN-γ (10 ng/ml)
and grown on RK3G9. The anti-CD44-treated cells had decreased IgG2a production,
compared to control. These data are representative of at least two separate
experiments.
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on immobilized RK3G9 or IM7 produced significantly less IgE, compared to control
cells, particularly at low cell concentrations (Fig. 14A). Indeed, when the data is
expressed as the amount of IgE produced per B cell, inhibition at all B cell concentrations
was seen in the anti-CD44-treated cells (Fig. 14B).
Isotype switching to IgG1 generally requires fewer cell divisions than switching to
IgE. IgM production requires no isotype switching. In order to determine whether
RK3G9 was inhibiting switching (IgG) or if it was simply preventing Ig secretion (IgM),
the supernatants were assayed for IgG1 and IgM. The production of both isotypes was
inhibited at all cell concentrations tested (Fig. 14C, D). This result suggests that Ig
secretion is inhibited under these conditions.
Finally, the B cells were also stimulated with LPS (25 μg/ml) + IFN-γ (10 ng/ml).
This promotes class switching to IgG2a; also note that IL-4, which could potentially be
aiding the RK3G9 in its effects, is absent. These cultures were assayed for IgG2a
production (Fig. 14E). The cells cultured in the presence of immobilized anti-CD44 Abs
exhibited a decreased proliferation (data not shown) as well as IgG2a production (Fig.
14E), both indicating that the inhibitory activity of RK3G9 was not dependent on the
presence of IL-4 and that other isotypes could be inhibited. Consistent with the
proliferation studies, when soluble RK3G9 antibody (1, 10, and 100 μg/ml) was added to
B cell cultures, it had no effect on the IgE production by B cells, as compared to control
cells (Fig. 15).
Interestingly, the anti-CD44-mediated inhibition was somewhat less at higher cell
numbers. It was therefore hypothesized that if a greater number of anti-CD44 antibodies
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Figure 15. Soluble RK3G9, even up to 100 μg/ml, was added to B cell cultures and had
no effect on B cell IgE production.
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were presented to the B cells, then perhaps inhibition would be seen at higher B cell
concentrations. A MAR18 (mouse anti-rat) antibody could be coated onto the plate and in
theory could “present” two secondary antibody molecules to the cells being cultured.
Hence, MAR18 (10 μg/ml) was coated onto the 96-well plates prior to a secondary
antibody coating of RK3G9 or C0H2. B cells were cultured as described in the Methods
section and grown for 3 or 8 days. The spread phenotype was observed in the MAR18RK3G9 cultures but not the MAR18-C0H2 cultures. Proliferation, measured via 3Hthymidine incorporation, of the B cells grown on MAR18-RK3G9 was less than that of
MAR18-C0H2 (Fig. 16A). However, the degree of inhibition was significantly less than
that of B cells cultured on RK3G9 alone. A likely explanation for this is the on-off rate
for the MAR18-RK3G9 interaction; it could mean that the B cell CD44 does not undergo
as much crosslinking as it does when immobilized anti-CD44 is present alone.
C. Cross-linking does not increase the ability of soluble RK3G9 to inhibit B cell
proliferation or IgE production. In reference to the lack of anti-CD44 ability to inhibit
proliferation when added to the cultures in solution, a hypothesis was formed and tested.
It was thought that if the RK3G9 could be “bound” (cross-linked) in solution rather than
on a plate – as clustering of CD44 on the cell surface is a prerequisite to causing
activation/signaling63 – then perhaps the soluble “cross-linked” RK3G9 could act as a
scaffold and mimic the plate-bound version of anti-CD44 presentation. Hence, an
experiment was set up wherein soluble RK3G9 (1 or 10 μg/ml) was combined with
biotinylated MAR18 and streptavidin in an effort to promote the hypothesized “soluble
scaffold”, and this combination was added to the cell cultures. Control cells were grown
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Figure 16. Mouse anti-rat (MAR18) antibody was coated as a primary antibody onto
plates, followed by a secondary antibody - RK3G9 or C0H2. The B cell cultures grown
on anti-CD44 exhibited some degree of inhibition as compared to the control, but it was
much smaller effect than what is seen without the primary MAR18 antibody. A,
proliferation of the B cells; B, IgE production.
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with no antibody (PBS). Analysis of the proliferative capacity (Fig. 17A) and the IgEproducing ability (Fig 17B) of the B cells incubated with the RK3G9 + biotinylated
MAR18 + streptavidin showed that there was a small anti-CD44 inhibitory effect on
these cells (30-50% inhibition).
Because it was thought that a soluble form of the anti-CD44 was more
physiologically relevant, a second type of crosslinking experiment was considered. There
were two ways to crosslink RK3G9 with micro-beads to make a physical “scaffold” in
solution: 1) add biotinylated RK3G9 to the cultures in conjunction with streptavidinlinked microbeads and 2) add unlabeled RK3G9 + biotinylated MAR18 + streptavidin
microbeads. Both options, plus controls, were used. IgE levels were tested after 8 days.
RK3G9 (10 μg/ml), when cross-linked to the beads via biotinylated MAR18, inhibited
IgE production (Fig. 18) by about 60% at lower cell concentrations. Hence, even crosslinking RK3G9 to make a sort of “physical scaffold” in solution did not fully mimic the
plate-bound environment.
D. CD44 knockout mice confirm RK3G9 specificity. RK3G9 was confirmed to bind to
only CD44 by using CD44 knockout mice. These CD44-/- B cells were harvested,
isolated, and cultured on RK3G9 or control for 3 days. A proliferation experiment
showed no inhibition of proliferation in the CD44-/- mouse B cells grown on RK3G9 (Fig.
19A). This showed that RK3G9 is not simply having a cross-effect on some other
molecule on the mouse B cell surface and is specific for CD44. Additionally, CD44v7
knockout mice were available, so the B cells from these were also cultured and tested as
above. These did respond to the anti-CD44-mediated inhibition (Fig. 19B), and we
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Figure 17. Proliferation by B cells grown with RK3G9 plus biotinylated MAR18 plus
streptavidin. PBS is the control in this initial experiment. A, Proliferation was not
inhibited by addition of RK3G9 + biotinylated MAR18 + streptavidin. B, Addition of the
“scaffold” materials did inhibit IgE production, but to a much smaller degree than platebound RK3G9.
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Figure 18. IgE production by B cells grown with RK3G9 plus cross-linking agents.
Biotinylated RK3G9 + streptavidin microbeads and biotinylated MAR18 + streptavidin
microbeads + 1 or 10 μg RK3G9 inhibited IgE production by about 50% at lower cell
concentrations, as compared to the control.
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Figure 19. The CD44-/- mice can not respond to RK3G9-mediated B cell inhibition of
proliferation. A, CD44-/- B cells proliferate normally when cultured with either anti-CD44
or control antibody (C0H2), and the IgE production shows no difference (B). C, CD44v7
KO B cells respond to the RK3G9-mediated inhibition, as shown by the IgE inhgibition
in the RK3G9-treated cells. C, Splenocytes from C57BL/6 and Balb/cJ mice had identical
reactions to RK3G9, thereby confirming that the CD44 knockout data was valid.
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conclude that RK3G9 does not bind to CD44v7. It is also possible that normal, activated
B cells do not express CD44v7.
The CD44 knockout mice were bred on the C57BL/6 background, and normal
C57 splenocytes were isolated and grown as discussed above. Comparison was made to
Balb/c splenocytes, as Balb/c is the strain used throughout these experiments. The
proliferative capacity of the Balb/c and C57 cells was equal, and equally inhibited by the
presence of plate-bound CD44 (Fig 19C).
E. FcγRIIb is not involved in the inhibition seen during B cell CD44 cross-linking.
FcγRIIb, the inhibitory gamma receptor found on murine B cells, can inhibit B cell
activation once it is bound and cross-linked. It was possible that the mechanism of B cell
inhibition by RK3G9 was due to FcγRIIb binding the Fc portion of the anti-CD44. To
rule this out, the effect of addition of an anti-FcγRIIb (2.4G2) Ab on the proliferation and
IgE production of B cells was examined. The B cells were pre-incubated with 2.4G2 for
40 min. on ice prior to culture in “IgE cocktail”. The data showed that, with the inclusion
of 2.4G2, the decrease in B cell proliferation (Fig. 20A) and IgE production (Fig. 20B)
caused by immobilized anti-CD44 Abs was identical to that seen in Figs 12A and 12B.
These data suggested that the inhibitory effect of plate-bound anti-CD44 Ab is a result of
specific interaction with CD44 expressed on B cells, rather than a non-specific effect
mediated by FcγRIIb.
F. The “Missing Factor” Hypothesis. It was hypothesized that the B cells could be
missing some important factor due to the RK3G9 effect on them; the proliferation and
even later IgE production was inhibited. They could make some factor under normal
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Figure 20. The inhibitory gamma receptor is not involved in the inhibition of IgE
production by B cells whose CD44 is crosslinked by an anti-CD44 antibody. A, Cultures
of B cells grown on immobilized RK3G9 or C0H2, regardless of addition of 2.4G2
addition or not, were significantly inhibited in their ability to proliferate (A) or produce
IgE (B). In the right-hand graph in A, 2.4G2 was added to cultures grown on RK3G9,
IM7, C0H2, or 2H10 (anti-CD23 control). Anti-FcgRIIb addition had no effect on the
RK3G9- or IM7-mediated inhibition of proliferation of these cells. Control cultures
provide the normal standard. These data are representative of at least two separate
experiments.
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conditions that helps them grow – perhaps a contact-dependent factor (as B cells
normally grow in clumps in culture) – and when cultured on anti-CD44 they could be
unable to make the necessary connections. Two different experiments were conducted; in
one, Cloning Factor was added, and in the other, supernatants from B cells grown in
normal conditions from days 3 and 8 were added back to the RK3G9-treated cultures.
Cloning Factor is normally used as a supplement to “feed” hybridoma cells –
ensuring that they get all the possible factors needed for growth. It is derived from a
conditioned culture supernatant from a murine macrophage-like cell line. This was added
at a 10% concentration to the RK3G9- or C0H2-treated murine B cells. Fig. 21 shows
that addition of Cloning Factor (CF) did not ameliorate the inhibition seen by culture on
RK3G9. This experiment was done prior to the regular FACS purification of the B cells,
and when the cells were only partially pure (~85% by Percoll gradient isolation), they
regularly partially overcame the RK3G9-mediated inhibition at the higher cell
concentrations (25,000/well). This may be noteworthy and will be discussed further in the
Discussion section.
Further testing of this “missing factor” hypothesis followed. It was possible that B
cells grown in culture produced a contact-dependent or –independent factor which helped
them to grow under normal conditions. The potential that receptors for these factors were
or were not expressed was an issue that could not be addressed at this point. An
experiment was set up to test this idea. Normal B cell cultures were grown for three or
eight days and supernatants were collected. New B cell cultures were set up and grown
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Figure 21. Addition of Cloning Factor to the cells did not cause a release of the
inhibition seen in the RK3G9-treated cultures. B cells grown on RK3G9 with the addition
of CF (Cloning Factor) were not released from the anti-CD44-mediated inhibition, as
compared to B cells grown on RK3G9 alone.
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on RK3G9 or control, with the media consisting of 25% supernatant from either the 3day or 8-day timepoints, with 75% new media. The results from the “day 3 supernatant
addition” experiment were unclear, but Figure 22A shows that for the experiment
involving Day 8 supernatants there was no effect of the “normal” B cell supernatant on
the proliferation of B cells grown on RK3G9. In fact, regardless of the type (RK3G9 or
C0H2) of supernatant added to the cultures, the B cells still responded to the anti-CD44
or control with similar proliferation. This suggests that the normal B cells do not produce
a “factor” and also suggests that RK3G9- treated cells are producing any “factors”
similarly to the normal B cells (as shown by the C0H2 B cells grown with 25% RK3G9
supernatant). The B cells incubated with Day 8 RK3G9 or “block” supernatant and
grown on RK3G9 or C0H2 all have lower proliferative values than the B cells grown
with 100% fresh media on either RK3G9 or C0H2; this is most likely a media effect. The
IgE results showed that RK3G9-treated cells were not relieved of the anti-CD44mediated inhibition by addition of either RK3G9 or C0H2 supernatants. The C0H2
culture grown in C0H2 supernatant had lower IgE-producing ability than its counterpart
grown in RK3G9 supernatant. This is likely due to media depletion; the C0H2
supernatants would have fewer nutrients left and more cellular waste product buildup in
the culture well after eight days than would the RK3G9 supernatant. This makes sense control cells grow very quickly and use up the media, while RK3G9-treated cells grow
very slowly (see Fig 12A). Another factor to be considered is that there may be
contaminating IgE in the supernatants from day 8, as the supernatants were not filtered
prior to addition back into fresh cultures. However, all things considered, there does not
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Figure 22. Mouse B cells grown with additive supernatants still respond to anti-CD44. A,
Proliferation of the cells grown for three days and incubated with day 8 RK3G9 or Day 8
“block” supernatants. The cells grown with RK3G9 or block supernatant and incubated
on RK3G9 showed slightly greater inhibition with reference to the normal (100% fresh
media) RK3G9-treated cells. As discussed in the text, this could be a media depletion
effect. B, Addition of C0H2 supernatant did not relieve the inhibition seen in the RK3G9treated cells. Again, the C0H2 control cultures differed somewhat and this is due to a
media depletion effect.

101

A.

30

-3

H thymidine x 10 (cpm)

40

Day 8 RK3G9 spnt - RK3G9 coat-plate
Day 8 RK3G9 spnt - C0H2 coat-plate
Day 8 block spnt - RK3G9 coat-plate
Day 8 block spnt - C0H2 coat-plate
control - RK3G9 coat-plate
control - C0H2 coat-plate

20

3

10

0
1

10

100

B cell number (x 1000)

B.
14
day 8 RK3G9 spnt - RK3G9 coat
day 8 RK3G9 spnt - C0H2 coat
day 8 block spnt - RK3G9 coat
day 8 block spnt - C0H2 coat

IgE μg/ml x 10

-3

12
10
8
6
4
2
0
1

10

B cell number (x 1000)

100

102
seem to be a “factor” in the supernatants that will provide relief from the anti-CD44
inhibition.
G. The effects of CD44 cross-linking on B cells are dependent on the type of B cell
activator used. In order to further explore the activation conditions in which CD44
cross-linking inhibited B cell activation, B cell cultures were stimulated with IL-4 + LPS
(25 μg/ml) and cultured on immobilized RK3G9 or C0H2. Under these conditions, B
cells grown on immobilized RK3G9 were significantly inhibited in comparison to control
cells, when proliferation (Fig. 23A) was examined. IgE production was similarly
inhibited (Fig. 23B). B cell cultures were also stimulated with just CD40LT + M15 + IL5 (no IL-4); the IFNγ experiment had indicated that IL-4 is not involved in the RK3G9mediated inhibitory effect. However, the inhibition of proliferation by RK3G9 in this
case was greatly decreased (Fig 23C). In addition, B cell cultures that were stimulated
with IL-4 + anti-IgM F(ab’)2 (10 μg/ml) on immobilized RK3G9 or C0H2 for 3 days
showed no effect due to CD44 cross-linking (Fig. 23D) in comparison to control cells.
This suggests that CD44 cross-linking has no effect on the B cells when they are
stimulated through the B cell receptor (BCR). Taken together, these data suggested that B
cell activation and/or differentiation is affected by cross-linking CD44 when the cells are
receiving their activation stimulus within the context of CD40LT or LPS; however, a
stimulus promoting BCR activation is not subject to RK3G9 modulation.
H. The CD44 cross-linking effects are limited to the initiation of B cell activation. In
order to explore the possibility that the effects of cross-linking CD44 on B cells were
dependent upon how soon after activation that the B cells encountered the anti-CD44
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Figure 23. B cell activation/differentiation is affected by CD44 cross-linking under a
variety of growth conditions. A, Effect of IL-4 + LPS stimulation on proliferation of
the naïve B cells. Immobilized RK3G9 significantly reduced the proliferation of the B
cells. B, CD44 cross-linking due to RK3G9 resulted in a decrease of IgE production,
when stimulated with LPS + IL-4. C, B cell cultures grown on RK3G9 and stimulated
with IL-4 + anti-IgM F(ab’)2 (10 μg/ml) were identical in proliferation to control
cells. D, B cell growth when stimulated by only CD40LT + M15 + IL-5 (no IL-4).
The RK3G9 inhibitory effect is less than when IL-4 is included (see Fig. 12A). These
data are representative of at least two separate experiments.
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antibody, B cells were stimulated with “IgE cocktail” and subsequently transferred, on
four successive days, onto RK3G9-coated plates. The supernatants were assayed for IgE
after 8 days in culture. Although cell numbers increased daily, the relative amount of IgE
made by the cells cultured on RK3G9, up to a Day 3 transfer, was significantly lower
than that made by cells cultured on control Ab. Day 4 transfer to RK3G9 or control
resulted in similar amounts of IgE production. Table 2 shows the relative amounts of IgE
(μg/ml) production by B cells either transferred to RK3G9 or C0H2, on successive days.
The IgE produced by all concentrations of cells transferred to RK3G9 was averaged and
is compared to that of cells transferred to control. The table clearly shows that B cells
which are exposed to activating stimuli for 3 days or less, prior to transfer, are still
subject to RK3G9-mediated inhibition. B cells which are activated for 4 days prior to
transfer to immobilized anti-CD44 Ab almost completely lose the ability to respond to
CD44 cross-linking. CD44 is known to be upregulated at the time of activation of a B cell
but also is downregulated by Day 4-5, when the cell begins to display a germinal-center
phenotype. This data suggests that there may be a link between time of activation and the
ability to respond to CD44 cross-linking.
I. Activation of the B cells is dependent on both anti-CD44 signals and the interplay
between different activation pathways. It is well known that there are three major B
cell pathways of activation: through the CD40 receptor, through the B cell receptor
(BCR), and through the Toll-like receptor (TLR). It has been shown here that B cells,
when stimulated by IL-4 + CD40LT or IL-4 + LPS, – activating the B cells through an
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Table 2. B cell ability to respond to anti-CD44 signals is absent by day 4 of
stimulation. B cells were first grown in culture with stimulation and then added to
RK3G9-coated plates after the specified number of days (left-hand column). The
middle column shows the amounts of IgE (ng/ml) production by B cells transferred to
RK3G9 and the right-hand column shows the amounts of IgE produced by cells
transferred to C0H2. The IgE produced by all concentrations of cells transferred to
RK3G9 or C0H2 was averaged and these are compared to each other. Parentheses
indicate the standard error of the mean. By Day 4, cells transferred to RK3G9 lost
their ability to respond to CD44-mediated inhibition and produced almost as much
IgE as the control cells. These data are representative of at least two separate
experiments.

107

TABLE II. B cell IgE response to anti-CD44 after X number of days
growth

Day of B
cell transfer
C0H2

Cells on RK3G9

Cells

Day 0

413.8 (101.3)

1371.1 (154.9)

Day 1

629.4 (188.5)

2257.6 (624.9)

Day 2

907.3 (333.4)

2850.1 (946.4)

Day 3

913.5 (275.8)

2714.8 (522.6)

Day 4

2160.4 (321.9)

2781.2 (567.1)

on

The numbers are average nanograms of IgE produced by these cultures as a whole; the
cultures were grown at a variety of concentrations from 500 cells/well up to 100,000
cells/well. The numbers in parentheses are the standard error of the mean.
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antigen-non-specific pathway – can be inhibited in their activation if CD44 cross-linking
has occurred. In addition, B cell activation is not inhibited by CD44 cross-linking if the
activation stimulus is anti-IgM F(ab’)2. Experiments were performed to examine the
possibility that one of the pathways activated by the stimuli could be downregulated by
BCR ligation during CD44 cross-linking. To address this question, purified B cells were
incubated with IL-4 + CD40LT + anti-IgM F(ab’)2 (10 μg/ml) (Fig. 24A) or IL-4 + LPS +
anti-IgM F(ab’)2 (10 μg/ml) (Fig. 25A) and they were grown for 3 days on RK3G9coated or C0H2-coated plates. The results were, in each case, that CD44 cross- linking
could still inhibit proliferation of the B cells (Fig. 24A and 25A), albeit less so with the
inclusion of BCR stimulation. B cells were then stimulated with IL-4 + anti-IgM F(ab’)2
– at increased concentrations of 25, 50, and 100 μg/ml – plus either CD40LT or LPS.
Again, they were grown on immobilized anti-CD44 for 3 days. Data for the 25 and 50
μg/ml anti-IgM are not shown, but at 100 μg/ml anti-IgM F(ab’)2, +/- CD40LT (Fig.
24B) or LPS (Fig. 25B), growth inhibition was no longer observed. While increased
stimulation of the BCR will stimulate a greater number of cells, so also will this increased
anti-IgM presence cause a phenomenon termed “receptor blockade” – which is what
occurs when receptors are downregulated in response to overwhelming stimulation, i.e,
the stimulation itself becomes inhibitory. One explanation for the data in Figs. 24B or
25B is that the receptors are downregulated and the BCR-stimulated culture did not
proliferate as well as it did at lower stimulation, thus creating a false impression that the
RK3G9-treated cultures were able to overcome the anti-CD44 crosslinking. However,
while this may be a factor, the relative differences between the cultures on RK3G9 and.
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Figure 24. B cell activation inhibition by CD44 cross-linking is dependent on the
type and amount of stimulation. A, Using 10 μg/ml anti-IgM F(ab’)2 + CD40LT + IL4 as the stimulus, B cells grown on RK3G9 are inhibited in their ability to proliferate.
The “RK3G9 – Ref.” is put in as a reference line (in 24A-B and 25A-B) and the data
is seen originally in Figure 12A with “IgE Cocktail”-stimulated cells. This line
illustrates maximal inhibition. B, Using an increased concentration of anti-IgM, - 100
μg/ml anti-IgM F(ab’)2 + CD40LT + IL-4 as the stimulus – B cells grown on RK3G9
are no longer inhibited in their ability to proliferate. These data are representative of
at least two separate experiments.
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Figure 25. A, Similarly, with 10 μg/ml anti-IgM F(ab’)2 + LPS + IL-4 as the
stimulus, B cells proliferation is again inhibited when they are grown on RK3G9,
though with less potency. B, B cells stimulated by 100 μg/ml anti-IgM F(ab’)2 + LPS
+ IL-4 did not respond with reduced proliferation to CD44 cross-linking. B cells
grown on RK3G9 proliferated similarly to those grown on the control antibody.
These data are representative of at least two separate experiments.
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C0H2 when stimulated with combinations including 10 or 100 μg/ml are still valid:
increasing amounts of anti-IgM in combination with CD40LT or LPS will overcome the
RK3G9-mediated effect.
J. In vivo experiment with RK3G9. The purpose of this experiment was to discover if
soluble anti-CD44 could cause an inhibition of B cell responses in vivo, as measured by
IgE production. IgE was chosen because it is very low prior to antigen exposure and
because that is the one immunoglobulin which was repeatedly seen to be inhibited to the
greatest degree in the in vitro experiments. Fig. 26A shows the setup for the experiment.
The mouse strain used was Balbc/J and the nine mice were given three subcutaneous
injections of RK3G9 – on days -2, 0, and 7. Alum-Ag (KLH-DNP) was also injected on
days 0 and 7. The mice were bled on days -3, 1, 4, 8, 11, 14, 21, and 28. The day -3 bleed
is a pre-bleed to ensure that the IgE levels in these mice was low (naïve). Fig. 26B shows
the IgE pre-bleed levels. Mouse #3 in the RK3G9 group had very high (~1.5 μg) IgE and
was not used for the remainder of the experiment. There were five mice in the C0H2
(control) group and four in the RK3G9 group. The IgE levels over the course of the 28day experiment are shown in Fig. 26C.
K. CD138+ B cells are decreased with RK3G9-treated cells. CD138 is known to be a
marker of plasmacytic differentiation in B cells. If the striking decrease in IgE production
was due to some “anti-CD44-induced defect” in becoming plasma cells, there should be
fewer CD138+ cells. B cells were isolated and grown with “IgE cocktail” on RK3G9 and
6B2 (anti-B220) antibodies at 10,000 (10K) cells per well – a concentration wherein the
immunoglobulin production was affected by the presence of RK3G9 and simultaneously
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Figure 26. IgE levels were unchanged by injection of RK3G9 in vivo. A, Schematic of
the time-course of the injections and bleeds for the mice. The mice were given three
subcutaneous injections of RK3G9 – on days -2, 0, and 7. Alum-Ag (KLH-DNP) was
also injected on days 0 and 7. The mice were bled on days -3, 1, 4, 8, 11, 14, 21, and 28.
B, IgE levels in the mice prior to injection. Mouse #3 in the RK3G9 group had very high
initial IgE levels and was not used in this experiment. C, IgE levels in the mice treated
with RK3G9 or C0H2. Pre-bleed IgE levels were not subtracted from the final results.
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where enough cells could be collected for FACS and Elispot analysis. The 6B2 antibody
was chosen as a control for this and remaining experiments due to its lack of signaling
properties under the conditions used to stimulate the cells, as well as its being a pan-B
cell marker. It also was chosen because it would flatten the cells onto the plate and act as
a control for the use of trypsin-EDTA (to get the cells off the plate and into a FACS
tube). It has been shown in this lab previously that 6B2 can be used as a control and has
no effect on proliferation or IgE production (data not shown).
For FACS analysis, cells were collected at day 6 and stained with CD138. Day 6
was chosen because most of the mouse B cells in culture are dead by day 8. While there
were greater overall numbers of cells recovered from the C0H2 cultures, the percentage
of live vs. dead cells was similar (FACS data, not shown). Figure 27 shows that cells
grown on control (6B2) were 30.71% positive for the plasma cell marker CD138, while
RK3G9-treated cells were 7.62% positive. The decrease in CD138 positivity in the
RK3G9-treated cells was not as great as the decrease in Ig production, but it was still
significant.
To confirm the data (above) suggesting that the anti-CD44-mediated inhibition
was at least partially due to formation of fewer plasma cells, Elispot analysis was
performed for the presence of IgG1- and IgE-bearing plasma cells. Again, the cells were
grown as stated above and collected at day 6. Elispot spot counts by light microscope
revealed that B cells grown on immobilized RK3G9 had formed fewer IgE+ plasma cells
than the control cells grown on 6B2 (Fig 28A). IgG1+ plasma cells (Fig. 28B) were also
counted and similar results were obtained.
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Figure 27. Fewer CD138+ cells are present with RK3G9-treated cells. This graph depicts
the FACS analysis of the CD138+ cells present after growth on RK3G9 or 6B2 for 6
days. RK3G9-treated cells are only 7.62% CD138+, while the 6B2-treated cells are
30.71% CD138+. This experiment is representative of four separate experiments.
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Figure 28. Elispot analysis showed that fewer plasma cells formed in the B cell cultures
grown on anti-CD44 (black bars), as opposed to those grown on 6B2 control antibody
(white bars). A, Elispot for IgE-forming cells; B, Elispot for IgG1-forming cells.
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These experiments, taken together and added to the immunoglobulin inhibition
data, strongly suggest that anti-CD44 is inhibiting plasma cell formation under these
experimental conditions.

II. Investigation of CD23b promoter region.
A. Efforts to “fix” the “defect” in the transcription initiation region of the CD23b
promoter. The relative similarities, as well as the lack thereof, between the CD23a and
CD23b promoters was discussed in the Introduction. The CD23a promoter has a TATA
box in the transcription initiation site; hence the first step was to put a TATA box into the
transcription initiation site in the CD23b promoter. The TATA box was added by cloning
the CD23b promoter into a pGL3 vector containing the TATA box used by CD23a. The
TATA box was cloned in to enhance the likelihood of RNA polymerase binding, so that
transcription could be initiated and mCD23b protein could be expressed. An initial
luciferase assay showed an almost 5-fold increase of CD23b promoter activity (with
stimulation by IL-4 + CD40L) over the basal level (no stimulation) and very little
increase with IL-4 alone, indicating that IL-4 is not the sole regulator of CD23b (Figure
29A). However, a second experiment measuring total luciferase activity of CD23b with
or without the added TATA box was still far below that seen with CD23a (Fig 29B).
The mCD23b promoter was also compared to the human CD23b (huCD23b)
promoter in luciferase vector constructs; used in this set of experiments were the human
CD23b promoter (pLUC+CD23BP) and the murine CD23b promoter with and without
the CD23a TATA box (pGL3-CD23b and pGL3-CD23b-TATA). These were transiently
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Figure 29. Activity of the CD23b promoter vs. CD23b-TATA vs. CD23a promoter. The
RLU20(relative light units) are a measure of the fluorescence of the luciferase, which
correlates with the activity of the promoter. A, The CD23b-TATA had a ~5-fold increase
in luciferase activity when stimulated with both IL-4 and CD40LT. B, Two additional
experiments revealed that CD23b-TATA had essentially equal activity to CD23b
promoter, and neither was as active as the CD23a promoter.
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transfected into either M12.4.5 cells or HEK293 cells. An initial luciferase assay
confirmed that the pLUC+CD23BP construct did work in the M12.4.5 cell line (Fig.
30A), suggesting that the mouse B cells do not appear to be lacking any proteins that
would inhibit CD23b expression. Additional experiments in either M12.4.5 cells or in
HEK293 cells (Fig. 30B) showed that both murine and human CD23b promoters had
some activity. Figure 30B shows the activity of the pLUC+CD23BP when stimulated
with various concentrations of huIL-4 vs. pGL3-CD23bProm with the previously
determined optimal IL-4 stimulation. pGL3-CD23bProm-TATA was also assayed in a
separate experiment & its activity was similar to that of pGL3-CD23bProm.
B. Creation of an antibody specific for the CD23a or CD23b isoform. Oligos for use
in RT-PCR were created to encompass full-length CD23a or CD23b, for the purpose of
cloning each isoform and transforming it into CD23-/- competent cells (see Materials &
Methods). Simultaneously, CD23a and CD23b peptides (using sequence from the
intracellular portion) were created and used to immunize rabbits (both services from
Open Biosystems, Huntsville, AL) in order to get a CD23 isoform-specific antibody. The
full-length CD23 protein would be harvested and used to test the rabbit serum containing
the isoform-specific antibody. The isoform-specific antibody would be used to confirm
the presence of CD23b in apical intestinal cells and to look for its surface expression also
in lymphocytes. Experiments by intracellular FACS staining and Western blot, using
IEC4.1 and 293 cells, showed that there was no isoform-specific antibody activity in the
rabbit serum for either CD23a or CD23b.
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Figure 30. Activity of the human and mouse CD23b promoters. The RLU (relative light
units) are a measure of the fluorescence of the luciferase, which correlates with the
activity of the promoter. A, The pLUC+CD23BP had a measurable luciferase activity –
approximately a 5-fold increase when stimulated with both IL-4 and CD40LT. B,
Luciferase vectors containing huCD23b or mCD23b were transiently transfected into
HEK293 cells. The human CD23b is shown in the left three bars and is stimulated with
various amounts of IL-4. It is compared to the mCD23b stimulated by a standardized
amount (see Materials & Methods) of rmIL-4, shown on the right. The greatest amount of
luciferase was produced when the human CD23b promoter was stimulated with 2000
U/ml of rhuIL-4, a non-physiological amount. The 20 U and 200 U of IL-4, which are
closer to physiological proportions, show that the human and mouse CD23b have similar
responses to IL-4 stimulation.

126

A.
Fold Increase (RLU)

6
5
4
3
2
1
0
IL-4

CD40LT

IL-4 + CD40LT

B.

Fold Increase (RLU)

10

8

pLUC+CD23BP
pLUC+CD23BP
pLUC+CD23BP
pGL3-CD23b

6

4

2

0
20 U IL-4

200 U IL-4

2000 U IL-4

human CD23b Promoter

rmIL-4

mCD23b promoter

127

Figure 31. RT-PCR for CD23b in the IEC4.1 cells. A, The first lane is the DNA ladder;
Lanes 1-5 are for CD23a; Lanes 6-10 are for CD23b. Lanes 1 and 7 are M12.4.5 cell
RNA; Lanes 2 and 8 are unstimulated IEC4.1 RNA; Lanes 3 and 9 are IL-4-treated
IEC4.1 RNA; Lanes 4 and 10 are IL-13-treated IEC4.1 RNA; Lanes 5 and 11 are IL4+IL-13-treated IEC4.1 RNA; and Lanes 6 and 12 are control reactions with no RNA
added. The M12 RNA is a positive control for CD23a and CD23b. IL-4+IL-13
combination treatment caused the most CD23b expression in the IEC4.1 cells. B, A
separate RT-PCR for CD23b in IEC4.1 cells. Lane 1 is unstimulated IEC4.1, Lane 2 is
IL-4 stimulated IEC4.1, Lane 3 is IL-13 stimulated IEC4.1, Lane 4 is unstimulated M12
RNA, and Lane 5 is the no RNA control. Lane 6 is the DNA Ladder standard.
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C. Analysis of murine intestinal epithelial cells for expression of the CD23b isoform.
With the exciting possibility that the CD23b isoform could be expressed in intestinal
epithelial cells, this angle was pursued and experiments involving IEC4.1 cells (a
Balb/cJ-derived intestinal epithelial cell line) were begun. Initially, reverse-transcriptase
polymerase chain reaction (RT-PCR) confirmed the presence of CD23b in these cells
(Fig. 31); however, a band corresponding to CD23a was also seen – and CD23a is not
expressed in these cells.153 As mentioned above, the proposed “isoform-specific
antibody” was tested on these cells as well as HEK293 cells transfected with full-length
CD23a or CD23b. After multiple tests by Western Blot and FACS, the results were
negative for CD23 and there was no “isoform-specific antibody” activity.
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DISCUSSION
I. Anti-CD44 studies on B cell activation.
The current study describes the effects of the immobilized anti-CD44 mAb
RK3G9 on the activation of purified murine B cells. When cultured in anti-CD44-coated
plates, proliferation was inhibited to a significant degree at all cell concentrations tested,
and immunoglobulin production was decreased. There was neither inhibition nor
enhancement of T cell growth when cultured on RK3G9. Soluble RK3G9 had no effect,
inhibitory or stimulatory, on the B cells, at any cell concentration or antibody
concentration tested. The inhibitory IgG Fc receptor, FcγRIIb, was not involved in this
anti-CD44-mediated inhibition, as demonstrated by the absence of any reversal of the B
cell inhibition when 2.4G2 was added to the cultures. Addition of microbeads to make a
soluble “scaffold” and mimic the plate-bound RK3G9 was only minimally successful.
Addition of B cell supernatants or Cloning Factor could not provide relief to the B cells
grown on RK3G9. When the B cells were stimulated and allowed to grow for 4 days
prior to exposure to immobilized anti-CD44 antibody, the effects of CD44 cross-linking
were lost. B cell responses to CD44 co-ligation by immobilized anti-CD44 Abs were
dependent upon the specific stimuli used to activate the B cells. Immobilized anti-CD44
in combination with CD40L or LPS stimulation resulted in inhibition of B cell activation,
whereas CD44 cross-linking had no effect on anti-IgM F(ab’)2-stimulated cells.
Combined addition of the activating cocktails indicated that BCR signaling could
completely reverse the inhibition seen. The plasma cell marker CD138 was decreased in
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the RK3G9-treated cells and Elispot analysis confirmed the anti-CD44-mediated decrease
in plasma cell numbers. Overall, the data in this dissertation suggests an important
regulatory role for CD44 cross-linking with respect to B cell activation and
differentiation. To my knowledge, this is the first report that immobilized anti-CD44
antibody is capable of inhibiting B cell function with the concurrent dependence of such
on the activating stimuli.
Immobilized
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rearrangements of the intracellular actin, tubulin, and vimentin, suggesting that B cells
are prepared to interact with other cells or the extracellular matrix (ECM).192 This is
proposed to regulate the activation status or the migration of activated B cells.192 SantosArgumeda, et al, examined the effect of immobilized anti-CD44 mAbs on murine B
cells.191 This report detailed the spreading of activated B cells on immobilized anti-CD44,
using various immobilized mAbs. The activation stimuli were either IL-4 + anti-IgM or
IL-4 + anti-CD38 and the cell concentration used was 106/ml. Resting (unactivated) B
cells were unable to spread on anti-CD44, but activated B cells spread and formed
dendritic-type processes with polymerized actin as a major component. The functional
parameters of B cell activation, however, such as proliferation or Ig production, were not
examined in the report. This spreading on immobilized anti-CD44, due to multivalent
cross-linking and increased affinity,101 could perhaps be similar to the integrin-mediated
form of cell adhesion.101 Inasmuch as anti-CD44 mAbs, as an “artificial ligand”, can
initiate clustering of CD44 molecules on the cell surface,193,194 - and this is a higher
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affinity pairing than CD44-HA – the signal given to the B cell via CD44 cross-linking
(by mAb) may be significantly stronger.
Soluble anti-CD44 antibodies have been shown to influence cell activation in
various cell types, including increasing binding to hyaluronic acid,195,196 triggering
hemopoiesis via cytokine release from bone marrow macrophages,197 activating T cells,95
and inducing cytokine/chemokine release from monocytes.198 A report by Rafi, et al,96
demonstrated that soluble anti-CD44 (KM201), as well as HA itself, triggered the
proliferation and differentiation of murine B cells. The parameters measured included cell
surface markers CD44 (upregulated) and CD45R (downregulated), and IgM production.
The results reported by this group contrast with the present study in that they found
soluble anti-CD44 Ab able to induce B cell activation. This can be explained by the fact
that, in the Rafi, et al, study, a different antibody was used and the cells were cultured at
six-fold higher density. Also of note in the previous study is the important fact that the
effect of anti-CD44 Abs or HA was studied on naïve B cells that had not been previously
activated, unlike the current study wherein the B cells were activated with a variety of
agents at the time of CD44 ligation. Additionally, this report deals with B cells whose
CD44 has been cross-linked by a specific immobilized antibody and which likely have
upregulated CD44 splice forms (unidentified at present).
Ingvarsson, et al, showed that naïve human tonsillar B cells, in response to
stimulation by soluble anti-CD44 (BU52) plus anti-CD40, would begin to display a
phenotype similar to that of a germinal center cell (upregulated CD10, CD95, and CD38;
also downregulation of CD24 and CD39).97 These naïve B cells also were stimulated
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with both anti-IgM + anti-CD40 plus or minus anti-CD44. The B cells that had the antiCD44 proliferated to levels 4x that of the cells without anti-CD44. One parameter not
tested in this experiment was the B cells’ ability to produce Ig. However, a separate study
by Hogerkorp, et al, shed some light on the genes that were being activated in naïve
human tonsillar B cells when they were stimulated with a combination of anti-IgM, antiCD40, and (soluble) anti-CD44 (BU52).110 The genes induced by anti-CD44 included IL1α, IL-6, and β2-adrenergic receptor (β2-AR), among many others; and the pattern of
genes upregulated by anti-CD44 suggested that CD44 may play a role in
immunomodulation and inflammation. In this report, soluble anti-CD44, up to 100 μg/ml,
in combination with IL-4 and CD40LT, had no effect either on the growth of murine B
cells or on their ability to produce IgE. It is not known whether this is an RK3G9-specific
effect or if this is due to an as yet uncharacterized difference between murine and human
CD44 or between the way that CD44 functions on a mouse B cell vs the human.
While the B cell CD44 crosslinking resulted in less proliferation and Ig
production, there was no increase in apoptosis. However, senescence is also a possibility
and proposed experiments include activated cyclin identification.
A single gene expression experiment was performed for the RK3G9-treated cells.
Freshly isolated B cells were grown at a concentration of 25,000 cells/well (96-well
plate) on RK3G9 or C0H2 for 48 hours and RNA was extracted. The Virginia
Commonwealth University’s DNA Core Facility provided the service of microarray
analysis (Affymetrix, Mouse 430A 2.0). A number of genes were upregulated or
downregulated in these cells, but only the most important are recorded here. Upregulated
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genes included actin binding proteins, Btg1 and Btg2 (B cell translocation genes,
antiproliferative), Ltbr (lymphotoxin B receptor), cyclin G1 and G2, BAX (pro-apoptotic
protein), Ikbke (Inhibitor of kappaB kinase epsilon), several members of the MAPK
family, actin, Rel, several members of the TNFR family, cyclin-dependent kinase inhibor
1a, SMAD7, Bcl-2 binding component 3, Abcg1 (ATP-binding and involved in ATPase
activity coupled to transmembrane movement of substances), Itpr5 (inositol 1,4,5triphosphate receptor 5, involved in ion channels), Alcam (activated leukocyte adhesion
molecule), CD80, several members of the Ras family, and Pias3 (protein inhibitor of
activated STAT3). Downregulated genes included Cyclin B1, Napa (N-ethylmaleimide
sensitive fusion protein attachment protein alpha, involved in intracellular transporter
activity in endoplasmic reticulum (ER) and Golgi), Sec61 (protein translocase activity,
ER), various transcription factors (no known pathways), CD22, AID (activation-induced
cytidine deaminase, involved in mRNA processing), members of the MAPK family,
members of the TNF family, caspase 3 (pro-apoptotic), immunoglobulin lambda and
kappa chains (variable 1), CD48, karyopherin (importin) beta 1 (protein-nucleus
transport), syntaxin 6 (intracellular transport), Bid (BH3 interacting death domain
agonist, regulation of apoptosis), CD36 (involved in transport and cell adhesion), various
adaptor and docking proteins (again, no known pathways), various proteins involved in
intracellular transport, and CD23. At a glance, these up- or down-regulated genes simply
confirm what was already known – that proliferation is inhibited and that Ig levels are
decreased. This data does suggest that 1) there is an actual decrease in Ig gene
transcription and this may lead to less Ig production at the protein level, and 2) the

135
decrease in mRNA expression of proteins involved in intracellular transport, especially in
the ER and/or Golgi apparatus to the membrane, may be part of the backdrop for the
decreased Ig secretion (Fig. 14) and the decreased numbers of surface Ig-bearing cells as
shown by Elispot (Fig. 28) seen on RK3G9-treated cells. Further gene chip experiments
are necessary to determine the reproducibility of the RK3G9 gene chip study and
ultimately elucidate the most important genes involved in the RK3G9-mediated inhibition
of B cell activation.
The inhibitory activities of the anti-CD44 Ab RK3G9 are most prominent at lower
cell concentrations, relative to the number of cells which are activated by the specific
stimulus used. The relationship between the B cell concentration and the functional
inhibition may be explained by the amount of CD44 “ligand” (RK3G9) that is bound to
the plate, relative to the amount of CD44 present on the cell surface. Obviously the latter
relates both to cell concentrations and to the CD44 upregulation achieved by activation of
the cells. Larger cell numbers would thus be anticipated to reduce the inhibitory activities
of the anti-CD44, which is the effect we observed. In addition, activation for a period of
time prior to culturing on immobilized anti-CD44 would cause an upregulation78 of CD44
on the B cell surface; hence, the limited amount of immobilized anti-CD44 has little to no
functional effect on these cells once they have increased in number as well as in their
surface CD44 expression. Here is an example: in the first stages of this project, the B
cells were purified by Percoll gradient, and the yield was 80-90% B220+ B cells as
measured by FACS. When these cells were grown on immobilized anti-CD44, the higher
cell concentrations (25,000 per well up to 100,000 per well) would invariably overcome
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the RK3G9-mediated inhibition and produce levels of IgE that were similar to the levels
produced by cells grown on control antibody. However, the control cells produced IgE
best at lower (less than 25,000 cells per well) concentrations of cells. It was hypothesized
that at higher cell concentrations that there was less anti-CD44 available for the greater
number of cells and the RK3G9-treated cells began to act like the control cells (at the
control cell low cell number). Interestingly, later in the project, the B cells were isolated
to 96-98% purity by FACS and this increase in IgE production by the RK3G9-treated
cells (at the higher cell numbers) disappeared. For the remainder of the project the cells
were isolated by FACS since their behavior on immobilized RK3G9 was more reliable –
they always reacted the same way at the same cell concentrations, and there was no
sudden increase in IgE production when the cell numbers were too high. The reason why
B cells at a lower purity should not respond in the same manner as B cells of higher
purity is still a mystery. During Percoll-isolation of splenic B cells, the T cells are lysed
using a combination of antibodies specific for T cell markers and guinea pig complement.
The Percoll gradient itself does, in theory, separate out the B cells from the other cells
(follicular dendritic cells, monocytes, eosinophils, etc) based on their density and rate of
migration during centrifugation. The only cells that could potentially contaminate the
Percoll-isolated B cells are the monocytes, FDCs, and NK cells. FACS for CD3-bearing
T cells showed only 1-3% T cells in the Percoll-isolated B cell populations (which were,
on average, 85% pure). Perhaps it is possible that another CD44-bearing cell type (any
leukocyte) was influencing the RK3G9-mediated inhibition.
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The IgE results in Fig. 16B showed some inhibition of IgE production by the
MAR18-RK3G9-treated cultures, but again the degree of inhibition was less than that of
cells grown on RK3G9 alone. This may be due to the “on-off rate” between plate-bound
MAR18 and the RK3G9; potentially, less anti-CD44 was presented to the B cells as is
usually found on an RK3G9-coated plate. The results suggested that this was true – that
there was less CD44 crosslinking and thus the IgE inhibition was ameliorated.
Interestingly, although RK3G9 had a profound effect on the B cells, it did not
have any effect on T cell proliferation. It has been shown repeatedly in the literature that
anti-CD44 can induce T cell proliferation and secretion of IL-236,37,91-93,199 and
stimulation of cytotoxic effector functions in CTL and neutrophils.90,92,200 Hyaluronan
binding to T cell CD44 is stimulatory,201,202 and the HA-binding function of T cells is
activated during an in vivo immune response.203 Although this report shows no inhibition
of T cell proliferation, the data also shows that there is no increase in proliferation,
although an increase might have been expected. Because B cells responded identically to
RK3G9 and the commercially available IM7, it is assumed that RK3G9 is similar to other
anti-CD44 antibodies and that cells that respond to anti-CD44 stimulation would respond
positively to RK3G9. However, the only parameter measured in this report’s T cell
experiments was proliferation. There may have been an effect on T cell IL-2 production
or some other parameter of T cell activation status, but none of them were tested.
Although, in other reports, B cells responded to soluble anti-CD44,96,97,110 the B
cells in this report did not; there was no increase in proliferation or IgE, nor was there the
decrease seen with immobilized RK3G9. Figures 17 and 18 illustrate the attempts made
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in this report to cross-link the anti-CD44 and make a “scaffold” in solution. This was
purported to mimic the plate-bound RK3G9. The results showed that the B cells could
respond to the “scaffolded” anti-CD44 to a certain extent (up to 60% inhibition), but the
>90% inhibition seen with immobilized RK3G9 was not evident.
Another explanation for the RK3G9 effect on B cells – a very simple one, in fact
– could be that the inhibitory Fc gamma receptor (FcγRIIb) was binding to the Fc portion
of the RK3G9 immobilized on the plate. The FcγRIIb, only found on B cells, has a
cytoplasmic immunoreceptor tyrosine-based inhibitory motif204,205 (ITIM) and has been
shown to inhibit the proliferation206-208 and Ca+ mobilization of B cells.209-211 This occurs
when FcγRIIb binds ligand, clusters, and is phosphorylated by Lyn, a Src-family
kinase.212-214 This provides a docking site for an SH2-domain-containing phosphatase
such as the inositol phosphatase SHIP (SH2-containg inositol polyphosphate 5phosphatase).210,215 Recruitment of SHIP leads to abrogation of BCR activation signaling
via hydrolysis of PIP3, leading to a blockage of the Ca+ signal.209-211 FcγRIIb activation
can also arrest BCR-triggered proliferation by inhibiting the activation of MAP kinases
and by inhibiting the recruitment of the anti-apoptotic protein kinase Akt.216,217 The data
in Figure 20 shows that activation of the FcγRIIb is not the reason that proliferation and
Ig production are so dramatically decreased. In this experiment, the cells were incubated
with 10 μg/ml 2.4G2 (anti-FcγRIIb) for 40 minutes on ice prior to culture on immobilized
RK3G9, and these cells were not released from the inhibition imposed by CD44-RK3G9
ligation. Although it was unlikely that an anti-rat antibody should affect mouse B cells,
the possibility existed and had to be invalidated.

-/-

The experiments involving the CD44
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mice were interesting in that they

confirmed that RK3G9 does bind to CD44 and not a similar protein on the B cell surface.
Also of interest is the data showing the Balb/cJ vs the C57BL/6 mice. RK3G9 interacted
with the B cells from the C57 mice in an identical manner to those from Balb/c mice,
suggesting additionally that RK3G9 is not interacting with a particular mutation in Balb/c
CD44. Unpublished data in this lab suggests that other molecules (ie, CD23) can have
strain-specific mutations which allow recognition only by antibodies which recognize
certain epitopes.
The possibility that there was a “missing factor” was intriguing. The B cells were
spread out on the plate and not allowed to “clump” and interact with the other cells, so
the most viable hypothesis was that there was a contact-dependent secreted factor – or
perhaps a physical signal was given between cells when they clump (binding protein &
ligand). The latter idea was supported by the data showing that higher cell numbers
tended to ameliorate the RK3G9-mediated inhibition, at least when the cells were at a
lower purity. The former idea was more easily tested and Fig. 22 shows that when normal
B cell supernatants (at 25% of the total media volume) were added to RK3G9-treated
cultures, there was no relief from the anti-CD44-mediated inhibition by addition of the
C0H2 supernatants. Another media supplement which is used to “feed” cells is Cloning
Factor (Fig. 21) – this was added to the media and also had no effect on the RK3G9mediated inhibition. The data from these experiments suggests that there is no “missing
factor” but further experimentation is needed. Another possibility is that there could be a
needed receptor for this “missing factor” which is itself not present. Another route for

140
this “missing factor”, in the case of Percoll-purified B cells, could be that it comes in the
form of help from another cell type, such as NK cells or monocytes. This is a likely
possibility, since Percoll-purified cells are typically 80-90% B220+ and 1-3% CD3+ (T
cells). The remainder would be NK, monocytes, dendritic cells, and other leukocytes.
Since CD44 is expressed on all leukocytes, the immobilized anti-CD44 could “activate”
some of these non-B cells, which could then provide “help” to the B cells by way of
cytokines or other factors.
The data from the in vivo experiment suggested that the in vitro RK3G9 effects
are not physiologically relevant. However, the only parameter measured in this
experiment was IgE; this immunoglobulin was chosen because in the in vitro work, it was
the most affected by immobilized RK3G9. Other reports of in vivo (murine) anti-CD44
use are usually treating specific experimentally-induced diseases involving conditions
such

as

vascular

disease,218

arthritis,103,219

experimental

autoimmune

encephalomyelitis,220 and autoimmune diabetes.221 The mice in the experiment in this
report were healthy and were simply being “vaccinated” in order to achieve upregulation
of immunoglobulin production. It was hoped that anti-CD44 treatment would decrease
the antibody response since the in vitro work suggested that the major parameter to be
affected was antibody (particularly IgE) production. In fact, this experiment proved very
little either way. If it did have an effect on IgE production, it likely would have been on
antigen-specific IgE, but total IgE was the parameter measured. Also, antigen-specific
IgM and IgG levels could also be telling. Another very important point to note is that
immune responses are typically localized and, physiologically, CD44-ligand interactions
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would be expected to be involved only in a very tiny area and number of cells. Hence, it
would be quite difficult to pinpoint any effect from the systemic injection of anti-CD44
antibodies.
The data in Table 2 suggests that RK3G9 ligation will elicit a response from the B
cells only if they have not been stimulated for very long. In other words, after the B cell
has been activated, signaling events occur and the cellular machinery begins to set the B
cells on the path indicated by the type of activation stimulus. At a certain point on this
path, the B cells are “committed”, and anti-CD44, which normally inhibits (or slows) this
pathway, cannot influence the B cells at this point. The data indicates that the B cells are
committed by day four, as the ratio of IgE produced by the RK3G9-treated cells vs
C0H2-treated cells remains at 1:3 until day four. It should also be noted that germinalcenter phenotypic markers have been shown to appear on or about day 4 and that the
surface CD44 expression drops on these activated cells.93
It is interesting that different types of stimuli, which of course activate different
signaling pathways, can modulate the effects of CD44 ligation by mAb (ie, RK3G9). As
shown in Fig. 14E, stimulation of the B cell cultures with LPS and IFNγ (minus IL-4)
modulated the anti-CD44 inhibition slightly, as IgE production was decreased but not as
dramatically as with CD40/IL-4 stimulation (Fig. 14B). This suggested that IL-4 was not
involved in the downregulation, but stimulation by CD40LT (no IL-4) only had
decreased IgE production by about 30-50%, which seemed to indicate that IL-4 could be
involved. However, the “best” way to signal a B cell to make IgE is to use IL-4,
especially in combination with CD40L (the “two signal” requirement), so it is possible
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that in its absence the control cultures also did not produce as much IgE as might have
been expected, leading to a false impression that IL-4 is involved in the RK3G9
inhibition of IgE.
RK3G9 was still able to inhibit B cell proliferation and production of IgE with
other stimuli such as LPS + IL-4. However, anti-μ stimulation resulted in complete
inhibition of the RK3G9 effect; that is, RK3G9 could not inhibit B cell proliferation
when they were being stimulated by anti-IgM. Interestingly, as Hathcock,222 et al,
reported, it is not simply the amount of CD44 expressed by a B cell that determines how
well it will bind to its ligand, but the type of stimulation can influence the CD44-HA
binding ability. This could be due to the CD44 isoforms induced by the type of activation
stimuli or the glycosylation of the CD44. Mouse B cells were tested for the expression of
CD44 variant isoforms using reverse-transcriptase polymerase chain reaction (RT-PCR),
but the results were unclear. It may also be that the anti-μ and anti-CD44 pathways do not
cross, or that the anti-μ signaling extinguishes the signaling initiated by RK3G9.
Three major signaling pathways are activated in the three types of stimulation
mentioned above. In the CD40-CD40L or the LPS-TLR interaction, the primary
commonality is the involvement of NFκB transcription factor.112,223 BCR signaling
involves ITAM-mediated activation of Ras, IP3, and DAG, with less involvement of
NFκB.116,117 Also, CD44 is known to be associated with some signaling molecules, such
as the src-related kinases lck and fyn.47,48 It is interesting that the B cells respond
differently to RK3G9 when they are activated by different types of stimulation. The
experiment in which combination of the activation signals resulted in the “rescue” of the
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LPS-activated cells suggests that the BCR signal can modulate the inhibitory capacity of
anti-CD44. Given this result, one could hypothesize that high level CD44 cross-linking
would restrict polyclonal B cell activation, but allow antigen-specific activation. Further
experiments will be required to determine if natural ligands of CD44 will result in the
same activities and if a similar regulation occurs in vivo.
If there was less IgE being produced under the influence of RK3G9, then the
logical hypotheses would be that: 1) isotype switching was not occurring or was being
slowed; 2) the “pathway” to plasma cell formation had been slowed and the cell died
before it could achieve plasma cell status (murine B cells only live 7-8 days in culture
and must undergo a certain minimum number of cell divisions before switching and
maturing to a plasma cell); 3) there was a “stop” signal given to the machinery during the
production of the IgE and it was not being secreted; or 4) there were fewer cells
becoming plasma cells. The data in Fig. 14 suggests that isotype switching is not being
inhibited, as all immunoglobulins are inhibited by RK3G9 treatment to a nearly equal
extent. FACS analysis for CD138+ cells – which are plasma cells – showed that the
presence of immobilized RK3G9 in B cell cultures decreased the number of plasma cells
by 75%. In addition, Elispot analysis for IgE and IgG1 confirmed that there were fewer
plasma cells in the RK3G9-treated cell cultures.
Overall, this set of experiments shows a profound effect of CD44 ligation on B
cell division, activation, and end-state plasma cell formation. Local inflammation,
wherein CD44 ligand would be upregulated on epithelial cells, does occur in vivo. This
new data involving CD44 ligation and the effects of different stimuli on the activation
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state of the cells suggests that ligation of CD44 inhibits non-antigen-specific reactions
and may enhance antigen-specific B cell responses. If this is true, then CD44-ligand
interactions may play a role in the activation of the localized B cell in vivo to promote
antigen-specific activation. In addition, activated B cells in the germinal center,
expressing upregulated CD44, could bind HA (or other ligand) on other leukocytes (also
expressing high levels of CD44 and potentially “presenting” a CD44 ligand). CD44
interactions between leukocytes can lead to activation of the cells involved and these
interactions may play a role in determining antigen-specific activation. Figure 32
diagrams an outline of this idea. This data is highly relevant to the study of B cell biology
and activation. Knowledge of each piece of the puzzle, particularly with regard to the
immune response to a “danger signal”, is an essential addition to our understanding of the
intricacies of B cell activation.
The mechanism for this decrease in plasma cell numbers is not known. It could be
intimately related to the slowing of proliferation and the probable subsequent decrease in
cell division. It could also be a decrease in plasma cell formation due to a specific signal
or simply a slowing of the process or impairment of immunoglobulin secretion. Further
experiments are needed to elucidate the mechanism(s) at work here. Levels of the
transcription factors XBP-1 and BLIMP1 would reveal whether the majority of the
RK3G9-treated B cell cultures were plasma-cell-committed, even if the immunoglobulin
secretion was inhibited. If so, then the rates of plasma cell formation could be elucidated
by a time course of RNA analysis for the levels of germinal-center-type transcription
factors such as PAX5 and BCL-6 vs the plasma-cell-type transcription factors BLIMP1
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Figure 32. Model for RK3G9 (anti-CD44)-mediated B cell antigen-specific activation.
The top panel depicts the in vitro model, in which immobilized anti-CD44 acts in concert
with anti-IgM to promote antigen-specific activation of the B cell, but inhibits nonantigen-specific activation. The bottom panel shows two possible scenarios in vivo: in the
peripheral B cell, CD44-ligand interaction (ligand on activated epithelial cells during
inflammation) could promote antigen-specific activation while inhibiting non-antigenspecific activation; similarly, in the B cell in the lymph node, CD44-ligand interactions
could regulate leukocyte interactions and activation and limit activation to only those B
cells that are antigen-specific.
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CD44 crosslinking via anti-CD44 antibody immobilized on plate:

B cell

IL-4 + CD40LT + IL-5
OR
IL-4 + LPS + IL-5

non-antigen-specific signals
result in inhibition of
proliferation, Ig production,
and plasma cell formation

anti-IgM

antigen-specific signals
result in reversal of the
anti-CD44 influence/signals

CD44

anti-CD44 on plate

Potential mechanism for CD44 regulation of B cell activation at work in vivo:

BCR bound to antigen
CD44

ligand binding on
epithelial cells

In presence of specific antigen,
B cell will proliferate and produce
antibody directed against antigen

peripheral B cell
BCR bound to antigen
CD44

ligand binding on
other leukocytes

lymph node B cell

In presence of activated T cells
expressing co-stimulatory molecules,
antigen-specific B cell will receive at
least two signals and will proliferate
and produce antibody

147
The work detailed in this report answered a few questions but has brought up
many more. Another thing that would be interesting to investigate further is the CD44
shedding/signaling aspect. Shi, et al, reports that anti-CD44 antibodies can induce CD44
shedding.224 Additionally, Okamoto, et al, and Murakami, et al, report the identification
of a new mechanism for direct signaling by CD44: a 2-step process wherein the CD44
ectodomain is cleaved by MT1-MMP,73,74 followed by cleavage of the transmembrane
(TM) domain by presenilin-dependent γ-secretase. This releases the CD44 intracellular
domain (ICD), which then translocates to the nucleus and act as a transcription
factor54,70,71 to potentiate activation of target genes (including CD44 itself54) in
conjunction with the p300/CREB-binding protein (CBP). The levels of surface CD44 on
the RK3G9-treated B cells were not determined in this report due to the difficulty of
getting the lower cell numbers off the bottom of the well in a 96-well plate – which
would also be the most important to find out as this is where the greatest inhibition was
seen. The levels of soluble CD44 – an indication of shedding – should have been
determined but were not. It would be most interesting to see if CD44 ICD is at work in
these cells and it can be hypothesized that it may affect a step in the pathway to becoming
a fully functional plasma cell. There is an antibody available (in the Hideyuki Saya
laboratory) called anti-CD44cyto which is directed against the CD44-ICD, so the
hypothesis could be tested. A great deal of work needs to be done before this hypothesis
could be substantiated, but it does propose a most intriguing mechanism for RK3G9mediated effects on mouse B cells.
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II. CD23b studies.
Expression of murine CD23b protein has long been difficult to pinpoint. Suter et
al,.225 examined the human CD23b and found that IL-4 stimulation of transiently
transfected B cell lines yielded a 2-4-fold increase in CD23b expression in
chloramphenicol acetyl transferase (CAT) assays. The comparable region in mouse was
analyzed here, both with and without a CD23a-like TATA box added; using luciferase
reporter assays, a similar induction was observed, as shown in Fig. 29. Both CD23b and
CD23b-TATA were equally stimulated. The increase in promoter activity was shown to
be additive depending on the stimulation: IL-4 alone caused a ~1.5-fold increase,
CD40LT alone caused a ~4-fold increase, and IL-4+CD40LT showed a ~5-fold increase.
However, the reporter activity of the CD23a promoter was significantly greater (~9-fold).
Ewart, et al, showed that the murine CD23a promoter is sensitive to only IL-4 and that
the STAT6 site most distal to the transcription initiation site was crucial for reporter
activity.172 The second STAT6 site, proximal to the transcription initiation site, which is
adjacent to an NFkB site, could not support IL-4-driven reporter gene expression when
the STAT6 site distal to the transcription iniation site was removed. The NFκB site was
unresponsive to stimulation by anti-CD40 and the data suggests that this region of the
CD23a promoter is silent with regard to cell surface receptor-initiated signals. CD23b
was far more responsive to signals initiated by extracellular stimuli. Both STAT6 sites
were physiologically competent and both had to be deleted before there was a loss of IL4-mediated reporter activity. In fact, one STAT6 site is sufficient for maximal activity.
The NFκB site was necessary for CD40-driven reporter expression. Anti-μ stimulation
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caused variable reporter expression, and activity was lost only after both of the putative
AP1 sites were deleted. This data suggests that AP1 family proteins may play a role in
the regulation of CD23b expression.168.
In this study, it was shown that human CD23b (pLUC-CD23BP) could be
expressed in a mouse B cell line and that its activity, as measured by luciferase
production, was similar to that of mCD23b and mCD23b-TATA activity. As will be
discussed in greater detail below, the human and murine systems may regulate their
CD23a and CD23b proteins very differently.
With regard to the experiments involving the “CD23 isoform-specific antibody”,
it was possible that the rabbits’ serum would contain an antibody that would be specific
and high affinity for both CD23a and CD23b. Peptides consisting of the CD23a or
CD23b intracellular tail sequence were used to immunize rabbits but these have a
difference of only the N-terminal 6 amino acids. Western blots were performed on both
the CD23b-expressing IEC4.1 cells and the CD23a or CD23b full-length-transfected 293
cells, with no positive results. Intracellular FACS was also performed with these same
cells as outlined above. The “CD23 isoform-specific antibody” reacted with its cognate
peptide, but had no activity with the intact protein, suggesting that the CD23 folding
“hid” the epitope to which it was directed. The failure of the anti-CD23 peptide reagent to
recognize CD23b means that detection of CD23 isoforms remains limited to RNA
methodologies.
The IEC4.1 cell line was created from Balbc/J mouse intestinal epithelial cells,
and these cells express CD23b. As discussed in the Introduction in detail, Yu, et al,
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showed that CD23b expression could be found in sensitized (food allergic) mouse
intestinal cells, as well as these cells. CD23b lacking (Δ) exon 5 or 6 was also found, but
only classical CD23b or CD23bΔ5 were shown to have the ability to bind IgE/allergen
complexes and were internalized in a sensitized animal.153 In later reports, Montagnac, et
al, showed that classical CD23b is most efficient in mediating the transepithelial
transport of IgE/allergen complexes, whereas CD23bΔ5 was shown to bind free IgE as
well as IgE/allergen complexes and may play a role in lumenal IgE recycling.185
Additionally, regulation of the intracellular trafficking of CD23a and CD23b was shown
to

be quite

different.

While

CD23a

exhibits constitutive clathrin-dependent

internalization, CD23b is stable on the cell membrane. The internalization of all murine
CD23 splice forms was due to a positive signal located in the cytoplasmic region of the
protein; however, this positive signal was negated by the presence of the CD23b-specific
exon. In addition to this, CD23b splice forms with a lack of exon 5, 6, 5 and 6, or 5, 6,
and 7, were constitutively internalized, which suggested that this region can negatively
regulate internalization. The human CD23a internalization signal was found to be present
in the CD23a-specific exon and human intestinal epithelial cell lines express both CD23a
and CD23b.160
In the present study, IEC4.1 cells were grown at the concentration and level of
stimulation as suggested by Yu, et al, and RNA was isolated for RT-PCR. M12.4.5
(Murine B cell line) RNA was used as a positive control for CD23a and FDC RNA was
used as a positive control for CD23b. However, while only rarely did the IEC4.1 cells
have a band indicating the presence of CD23b, they almost always had a band indicating
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CD23a. The PCR was done repeatedly with the utmost care but the CD23a presence was
unvarying, suggesting that either the IEC4.1 cells do indeed express CD23a, or there was
repeated contamination of either the cell line or the RNA derived from it.
There are more interesting aspects of CD23 – especially CD23b – yet to be
discovered. In particular, the question of the regulation of CD23a vs CD23b promoters in
human vs mouse – how are the two regulated and what makes them different? Then the
expression of the CD23a vs CD23b protein - is it entirely due to the inherent structure of
the protein itself or is it also partially due to the regulation of the promoters and the cell
type, as well as the species? Why are the CD23a and CD23b different between species –
does the answer lie in the promoter or in the protein itself or in the cell type(s) that
expresses the protein? The answers to these questions are potentially very important with
respect to the further elucidation of the role that CD23 isoforms and splice forms play in
allergic disease.
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